CI Atlas · Print-friendly overview
All modules at a glance
One-page summary of all twelve Objective-Measures modules with level tags, standfirst paragraphs, and the section table-of-contents per module. Use the print button below to generate a portable PDF reference, or click through to the full interactive module pages. The companion /glossary, /references, and /progress pages live separately.
The cochlear implant is often called the first device to restore a human sense — an achievement resting on a 200-year-old idea and a contested half-century of work. This opening chapter traces the arc from Volta's electrical 'sound' through the 1957 Paris first, William House's persistence, the single- vs multi-channel fight, the speech-coding breakthrough, and the approvals and consensus that made it accepted therapy.
Sections
The implant's lineage runs back to the invention of the battery: around 1800 Volta put probes in his own ears and heard a sound — the first record that electricity can create hearing. The insight then lay nearly dormant for 150 years, because the idea had arrived long before the electronics, microsurgery and cochlear understanding needed to use it.
Sections
If the cochlear implant has a birthday it is in 1957, in Paris, when engineer André Djourno and surgeon Charles Eyriès placed a wire directly on a deaf patient's auditory nerve and drove it with an induction coil. The patient heard sounds and rhythms, though not speech. The device soon failed, but the principle was proven — and word of it crossed the Atlantic to William House.
Sections
Proof of principle is not a usable device. That step was the work of the Los Angeles otologist William House, who with engineer Jack Urban built and refined the first wearable single-channel implant through the 1960s–70s, against deep scepticism. One electrode conveyed the sound envelope and powerfully aided lip-reading but not open-set speech — a real benefit, and a limitation that defined the next era.
Sections
For a decade the field split over one question: is one electrode enough, or are many essential? The answer was decided by the cochlea itself — a frequency analyser that encodes pitch by place, which a single channel cannot imitate. Multichannel recipients achieved open-set speech that single-channel users rarely did, and once that was reproducible the debate was over.
Sections
The multichannel implant has no single inventor. Simmons at Stanford showed multiple electrodes evoke different pitches; the UCSF group of Michelson and Merzenich built the multichannel approach that became Advanced Bionics; and the Utah Ineraid served as the research platform for the speech-coding work to come. The modern device is a synthesis of these parallel American threads alongside the Australian effort.
Sections
If one program turned multichannel implantation into a world standard, it was Graeme Clark's in Melbourne. Driven partly by his deaf father, Clark solved the electrode-array and insertion problems, implanted his first patient (Rod Saunders) in 1978, and partnered with industry to create Cochlear Ltd; the Nucleus 22 reached FDA approval in 1985 and set the template for the modern implant.
Sections
Europe was central to the multichannel era. The French surgeon Chouard built an early multichannel device in Paris, continuing the French line, and in Vienna the Hochmairs developed the implant — with long, flexible arrays — that became MED-EL, a leading global manufacturer. Today's three dominant makers trace to distinct Australian, Austrian and American programs.
Sections
The biggest leap in implant performance came not from new hardware but from a new way of using it. Earlier strategies drove electrodes simultaneously, so currents overlapped and interacted, blurring spectral cues. In 1991 Wilson and colleagues introduced continuous interleaved sampling (CIS) — staggered, non-overlapping pulses — and speech scores jumped immediately for the same hardware. How you drive the electrodes can matter as much as how many there are.
Sections
A device can work and still not be accepted. FDA approval of the single-channel device (1984), the multichannel Nucleus (1985) and — decisively — children (1990, tied to the sensitive period), together with the NIH consensus statements (1988 conference, 1995 statement), turned the cochlear implant from contested experiment into standard, reimbursable therapy endorsed for adults and children.
Sections
Once accepted, the question shifted from whether to implant to whom — and candidacy kept widening: the audiometric bar fell, residual hearing became something to preserve, the age dropped toward infancy, one ear became two, and new categories opened (electric-acoustic/hybrid and single-sided deafness). The arc runs from a last resort for the totally deaf toward a broad hearing-restoration therapy.
Sections
The newest movement in the implant's history is about cost and access. After the Western and Australian makers — and the French Neurelec/Oticon line absorbed by Cochlear in 2024 — a new generation in China (Nurotron, Listent), Korea (TODOC) and India is driving the price down. India's story runs from the DRDO/SBMT indigenous-implant effort born of Abdul Kalam's vision of a ~₹1 lakh bionic ear (an aspiration whose device details remain limited) to the made-in-India Neubio — turning the device from a luxury into a global, more equitable technology.
Sections
The story that began with Volta arrives at the most successful neural prosthesis ever built — the first to substantially restore a human sense, in over a million people — with the 2013 Lasker Award to Clark, Hochmair and Wilson. The history teaches how breakthroughs really happen, leaves access as its unfinished challenge, and serves as the human prologue to the rest of the atlas.
Sections
Normal hearing is a chain of transformations from an air-pressure wave to a cortical percept. This foundations module follows sound through all seven stages, fixes the two organising principles (tonotopy and the active cochlea), and shows exactly where a cochlear implant cuts into the chain — bypassing the mechanical front end to drive the surviving auditory nerve.
Sections
Hearing begins in the air. Sound is a pressure wave whose frequency is heard as pitch and amplitude as loudness; level is measured on the logarithmic decibel scale; complex sounds are sums of pure tones (their spectrum), and speech is a harmonic series shaped by formants. Every property becomes a design constraint for a hearing device.
Sections
The conductive front end. The pinna and canal collect and filter sound (with ~20 dB of speech-band resonance); the middle ear is an impedance-matching transformer (area ratio plus ossicular lever) that couples low-impedance air to high-impedance cochlear fluid; failures cause conductive hearing loss. A cochlear implant bypasses all of it — re-using only the stapedius reflex.
Sections
How the cochlea sorts sound by frequency. The fluid scalae and basilar membrane; von Békésy's travelling wave; the stiffness gradient that maps high frequencies to the base and low to the apex (tonotopy); the Greenwood place-frequency equation; why sharp tuning needs an active cochlea; and how a cochlear-implant array inherits the tonotopic map.
Sections
The sensory machinery on the basilar membrane: the organ of Corti, the tectorial shearing motion, and the two hair-cell populations — a single row of inner hair cells that sense and drive ~95% of the auditory nerve, and three rows of outer hair cells that amplify. Stereocilia and tip links; and the inner-hair-cell-to-nerve step the implant replaces.
Sections
How a hair cell turns movement into current: the endocochlear potential (~+85 mV) and the cochlear battery, the molecular tip-link machinery (cadherin-23, protocadherin-15, myosin-1c) gating the transduction channels, the upside-down depolarising potassium current, the stria vascularis and the potassium-recycling loop that keep the battery charged, the genetics of deafness that follow (connexin-26, KCNQ4, Jervell–Lange-Nielsen, Usher), and the molecular machinery the implant bypasses.
Sections
Why the living cochlea is so sensitive and sharply tuned: outer-hair-cell electromotility (Brownell) and the motor protein prestin (Dallos), the active feedback that boosts and sharpens the travelling wave (~40–60 dB), compression and dynamic range, efferent gain control, the threshold/tuning/recruitment triad of its loss, and why electric hearing has no amplifier.
Sections
Sound the ear makes. Kemp's discovery; emissions as the audible fingerprint of the active outer-hair-cell amplifier; spontaneous, transient-evoked, and distortion-product types; what present vs absent means (sensitive, not specific); the auditory-neuropathy pattern; the engine of newborn hearing screening; and their diagnostic, not programming, role for the implant.
Sections
The cochlea's output cable: the spiral ganglion and its type I and type II fibres, the V-shaped tuning curve and characteristic frequency, spontaneous-rate classes and the S-shaped rate-level function, the dynamic-range problem solved by selective listening, two-tone suppression and adaptation, and the type I neurons a cochlear implant stimulates directly.
Sections
Coding of intensity & loudness — firing rate and fibre recruitment, the power-law growth of loudness and loudness summation, the ~120 dB dynamic range and its collapse in hearing loss, recruitment, and how electric hearing codes loudness in a narrow current window with no recruitment — the physiology behind T and C levels.
Sections
Coding of frequency & pitch — the place code from tonotopy and the temporal code from phase-locking, the ~4–5 kHz phase-locking rolloff, the volley principle, periodicity pitch and the missing fundamental, and why an implant (mostly place, only coarse timing) makes fine pitch and music hard.
Sections
Where the coded signal goes after the nerve: the ascending pathway from the cochlear nucleus through the superior olive, inferior colliculus, and thalamus to the auditory cortex; the cochlear nucleus's feature-extracting cell types; preserved tonotopy and crossed pathways; cortical organisation; central plasticity and the sensitive period; and why an implant's success depends on the whole chain.
Sections
What two ears add: localising sound by interaural time and level differences (the duplex theory), the medial superior olive computing timing (ITD) and the lateral superior olive computing level (ILD), head shadow, summation, spatial release from masking, and how bilateral and bimodal cochlear-implant fitting tries to restore them.
Sections
A cochlear implant delivers a signal, not hearing — the brain must learn to hear with it, and whether it can depends on plasticity. The genes lay a scaffold; the environment, arriving in time, wires the auditory system. This overview introduces activity-dependent development, the sensitive period, and why the timing of an implant is a question about the plastic brain.
Sections
Some things the brain can learn only at certain times. From Lorenz's imprinting to birdsong to human language, development runs on a timetable: experience must coincide with a stage of maturation or the chance is lost. This module distinguishes hard critical periods from softer sensitive periods and locates the auditory window a cochlear implant must reach in time.
Sections
What we know about deprivation came first from the eye. Hubel and Wiesel closed one eye of a young animal and watched the visual cortex rearrange around the loss — a central, time-limited blindness in a structurally normal eye. This module draws the lesson for prostheses: a perfect signal cannot help a brain whose pathway was never built.
Sections
A patch of cortex is not committed at birth to a sense — it becomes whatever its inputs make it. Damage a whisker and its cortical barrel never forms; reroute the eye and auditory cortex builds a visual map. The cortex is pluripotent and competitive, which explains both the danger of deafness (its territory is claimed by other senses) and the possibility of the implant.
Sections
A silent ear does not leave a silent-but-intact brain. From the cochlear nucleus upward the deprived auditory system remodels — nuclei shrink, cells dwindle, the timing-critical endbulb of Held atrophies — and the deaf white cat shows it is the absence of activity, not the organ loss, that does it. The implant feeds a brain already changed by deafness, in proportion to its duration.
Sections
When a sense is lost its cortex is not left empty — the spared senses move in. A blind person reads Braille with visual cortex; a deaf person's auditory cortex comes to process vision. This takeover is functional, and double-edged for the implant: useful compensation, but a contested auditory cortex that favours implanting before reorganisation entrenches.
Sections
How old is too old? The cortical P1 response answers it without opening the brain: implanted by ~3.5 years a child's P1 latency reaches normal (the pathway matures); after ~7 years it stays abnormal. The biomarker turns the sensitive period into a measurable timeline and is the scientific backbone of newborn screening and early implantation.
Sections
Against shrunken nuclei and atrophied synapses the implant can look crude, yet it works — because the developing system needs organised activity in time more than perfect sound. Stimulation rescues the endbulb of Held and reclaims auditory cortex with use. The implant prevents deprivation; the brain builds a working auditory system around it.
Sections
Here the biology becomes a number on a clinic chart. In a child deaf from birth, age at implantation is among the strongest predictors of outcome as the sensitive period closes; in an adult deaf after language, age matters far less because the linguistic brain is already built. Duration of deafness and residual hearing refine the picture — and all of it argues for implanting early.
Sections
Plasticity does not end with childhood. Adult cortical maps reorganise after injury, and training enlarges the cortical representation of practised sounds. This residual plasticity — more limited and effortful than a child's — is what a newly implanted adult relies on, and it is the cellular basis of acclimatisation and auditory rehabilitation after switch-on.
Sections
The brain's hardest auditory computations come from comparing the two ears — and that comparison is built by balanced experience during a sensitive period. Deprive one ear, or restore the two years apart, and the system develops an aural preference. This is the developmental argument for bilateral and near-simultaneous implantation.
Sections
A closing synthesis: a brain cannot maximise both learning and stable memory, so the windows must close to protect what was built — an adaptation, not a flaw. The whole chapter reduces to one idea: the environment must reach the brain in time. The implant is a way of delivering it, and its successes and limits are the successes and limits of plasticity.
Sections
The cellular companion to the plasticity chapter: what deafness and the implant do to the tissue of the auditory pathway. In two halves — deprivation (loss of hair cells removes the input that keeps the pathway alive, and degeneration climbs from the spiral ganglion up) and rescue (electrical stimulation re-supplies activity, partly arresting and reversing the decline). The pathway is a chain of dependence, and the implant joins it at the spiral ganglion.
Sections
A brief tour of the healthy pathway as a chain of relay stations from hair cell to cortex, each built and maintained by the input from the one below (activity-dependence). The spiral-ganglion neuron in three parts — peripheral process, soma, central axon — and where the implant joins the chain. The baseline the rest of the chapter watches change.
Sections
Most sensorineural deafness begins with hair-cell loss. But the hair cell also supplies the spiral-ganglion neuron with activity and trophic support, so its death deafferents the neuron, which degenerates secondarily — peripheral process first, cell body more slowly. The trigger for the whole cascade, with the exception of conditions where the nerve is the primary lesion.
Sections
The spiral-ganglion neuron is what deafness slowly kills and what the implant stimulates. Peripheral processes go within weeks; the cell bodies decline gradually over months–years, at a rate set by cause, onset age and duration — so a stimulable population usually persists even after decades (human temporal-bone evidence). Survival shapes, but does not determine, implant outcome.
Sections
An electrode array is only as good as the nerve it drives. Each contact stimulates the surviving spiral-ganglion neurons nearby — and that population is uneven. A contact over a healthy patch makes a good channel; one over a neural gap does not, however much current it is given. The spatial pattern of survival, the inward shift of the excitation site after peripheral-process loss, and why objective measures probe this substrate.
Sections
Cross the first central synapse and deprivation becomes vivid: the cochlear nucleus shrinks, and the giant endbulb of Held — built for microsecond timing — atrophies (Ryugo, deaf white cats), degrading temporal precision from the first central synapse up. The developing brainstem is most vulnerable, and the endbulb is the structure chronic stimulation was later shown to partly rebuild.
Sections
Deprivation continues upward. The superior olivary complex compares the two ears for localisation and is built on balanced binaural input, so unilateral deafness — or a long inter-implant delay — skews it toward the hearing side (aural preference). The inferior colliculus's tonotopic map is reshaped by experience and by stimulation. The cellular case for bilateral, well-timed implantation.
Sections
At the top of the pathway, early deafness arrests the auditory cortex's maturation and lets vision and touch colonise its territory (cross-modal reorganisation). A cortex that never matured needs input early; one already taken over is a harder target, and greater cross-modal takeover tracks poorer late-implant outcomes — the morphological face of the plasticity chapter's timing message.
Sections
The mechanism of rescue. In deafened animals, the ear that is chronically stimulated by an implant retains more spiral-ganglion neurons than the untreated ear (Leake). Activity is trophic — the renewed firing, with neurotrophins like BDNF and NT-3, partly substitutes for the lost hair-cell input. The implant is not only a way to hear but a support for the nerve it drives — a reason to implant early and stimulate consistently.
Sections
Stimulation can partly reverse deprivation, not just slow it: chronic stimulation regrows the atrophied endbulb of Held (Ryugo 2005), re-shapes central maps, and resumes arrested cortical maturation if early. But it cannot regenerate lost hair cells or dead neurons, regrow lost peripheral processes, or reopen a closed window. Damage is fast and easy; repair slow and partial — and earlier is always more reversible.
Sections
The chapter's biology turned into the rules clinicians use: implant early (for two independent reasons — the fading peripheral substrate and the closing cortical window); expect timing tasks (localisation, speech in noise) to lag because the precise-timing machinery is most degraded; implant both ears without long delay; and read the nerve channel by channel via objective measures, deactivating dead channels.
Sections
The forward look. Today we preserve the surviving pathway through the implant's own trophic stimulation and atraumatic, hearing-preservation surgery. Emerging approaches would actively protect and regrow it — drug- and neurotrophin-eluting electrodes, local BDNF delivery to keep neurons alive and draw their processes toward the electrode. On the horizon: hair-cell and neuron regeneration. A better-protected substrate gives the implant more to work with.
Sections
Before a single implant is considered, a prior question must be answered: how big is the problem, and where does it fall hardest? This overview counts hearing loss — beginning in India, where the burden is heavy, young and largely preventable, then widening to a world in which one in five already lives with hearing loss — and sets the public-health frame on which the rest of the atlas rests.
Sections
Every prevalence figure is the answer to a question settled before counting began: what counts as hearing loss, how severe, in which ear, over what period? This module sets out the measuring instruments — the WHO grades of severity, prevalence versus incidence, and the disability metrics (DALYs, YLDs) that let an invisible, non-fatal impairment be weighed against diseases that kill.
Sections
India is home to roughly a sixth of humanity and to about 63 million people with significant hearing loss. This module unpacks what that number contains: who these people are, how young they are when hearing fails, where they live, and why so many never reach a clinic — a burden that is heavy, disproportionately young, and concentrated among those least able to pay.
Sections
Ask why an Indian child or adult cannot hear and the answer is, more often than not, something that could have been prevented. This module maps the distinctive Indian causal mix — chronic ear disease, consanguinity-amplified genetics, birth-related injury, noise, ototoxic drugs and vaccine-preventable infection — and sorts it by what could have been prevented or treated.
Sections
Chronic suppurative otitis media — the draining, perforated ear — is the signature cause of preventable hearing loss in India and South Asia. This module follows the otitis-media spectrum, sizes the global burden the developing world carries, explains why the resulting loss is conductive and usually treatable rather than implant territory, and weighs the real developmental harm of the neglected ear.
Sections
Some causes block a healthy inner ear; noise and ototoxic drugs destroy it. Both kill cochlear hair cells, causing permanent sensorineural loss — yet both are preventable. This module covers the NIOSH noise dose and exchange rate, India's noisy environment, aminoglycoside and platinum ototoxicity, the tuberculosis connection, and the mitochondrial m.1555A>G susceptibility variant.
Sections
Much severe childhood deafness in India is written in the genome and surfaces through who marries whom. This module explains autosomal-recessive inheritance and the 1-in-4 risk, how consanguinity raises the chance both parents carry the same rare allele, consanguinity in India, the central role of GJB2/connexin-26 and the W24X founder mutation, and the implications for counselling and candidacy.
Sections
Of all the hearing loss in this chapter, the loss a child is born with matters most, because it strikes the brain when it most needs sound. This module covers the 1–2 per 1000 birth prevalence, the roughly even genetic/acquired split, congenital CMV and rubella, perinatal risk factors, and the race against the developmental clock that drives newborn screening and early implantation.
Sections
A deaf newborn looks exactly like a hearing one, so without a deliberate test congenital loss goes unnoticed until a child fails to speak. This module sets out the case for universal newborn screening, the evidence that early identification transforms language, the 1–3–6 framework, the OAE and automated-ABR tools (and why AABR catches auditory neuropathy), and India's coverage challenge.
Sections
Widening from India to the world: more than 1.5 billion people (about 1 in 5) already live with hearing loss, projected to reach 2.5 billion (1 in 4) by 2050. This module explains why the burden is rising (population growth and ageing), why it falls disproportionately on low- and middle-income countries with the fewest ear-care professionals, and how India is a concentrated example of the global pattern.
Sections
A prevalence figure measures how many, not how much. This module follows the cost of unaddressed hearing loss across life — language and schooling in childhood, employment and income in working life, and cognition in old age, where it is the largest modifiable dementia risk factor — totalling a WHO-estimated US$1 trillion a year, and making treatment one of medicine's highest-return interventions.
Sections
The chapter's conclusion: two tasks — prevent what can be prevented, and treat what cannot. This module covers the levels of prevention, India's NPPCD, the WHO ear-and-hearing-care agenda, and the access gap — the leaking pathway from candidate to implanted child, the ADIP funding scheme, and why access, not technology, is the limiting factor in Indian cochlear implantation.
Sections
Every implant candidate shares one diagnosis, yet results vary enormously — and much of that variation is genetic. This overview sets out how common and how genetic deafness is, why the heterogeneous cause matters for the implant, and the chapter's organising idea: the gene predicts the site of the lesion, and the site — cochlea vs spiral ganglion — predicts the result.
Sections
The first question of any genetic deafness is whether it travels alone. About 70% is non-syndromic and 30% syndromic — and recognising a syndrome can change everything from implant urgency to a life-saving cardiac referral. This module also exposes the trap: Usher and Pendred look non-syndromic at birth, and only genetic testing unmasks these mimics in time.
Sections
Genetic deafness is transmitted in four patterns — autosomal recessive (most non-syndromic loss), autosomal dominant (often progressive), X-linked (POU3F4 and the surgical gusher), and mitochondrial (maternal, and the aminoglycoside-susceptibility variant). This module reads each pedigree and draws out its recurrence risk, example genes, and clinical consequences.
Sections
If one gene deserves its own module it is GJB2 — connexin-26 — which causes about half of severe-to-profound recessive non-syndromic deafness. This module shows how connexin gap junctions recycle potassium through the cochlea, why their failure spares the auditory nerve, and why GJB2 deafness is therefore among the best performers after cochlear implantation.
Sections
More than a hundred genes can cause non-syndromic deafness; one way of organising them turns the list into a prognosis — sort by where in the ear they act. This module maps the genes into membranous-labyrinth (upstream of the electrode, good outcome) and spiral-ganglion (the implant's target, variable/poor), the bridge to the spiral-ganglion hypothesis.
Sections
A condition caused by any of a hundred genes poses a brutal testing problem. This module follows the leap from Sanger sequencing (one gene at a time) through fixed-mutation microarrays to targeted next-generation panels (OtoSCOPE) that screen every known deafness gene at once — the technology that made genetic diagnosis, and prognosis, practical.
Sections
Genetic testing should move to the front of the cochlear-implant evaluation. This module sets out the paradigm — comprehensive panels for apparent non-syndromic loss, phenotype-directed testing plus referrals for syndromic loss — and what a result changes: fewer other tests, altered surgery (POU3F4 gusher), sharper selection and grounded counselling, with the caveat that a negative panel does not exclude a genetic cause.
Sections
The chapter's central thesis: because a cochlear implant injects its signal at the spiral ganglion, lesions upstream in the membranous labyrinth are bypassed (good outcome) while lesions in the spiral ganglion itself are not (poor). This module gives the anatomical logic, the supporting evidence and the honest limits of the principle that turns a genotype into a prognosis.
Sections
The spiral-ganglion hypothesis made gene by gene. Membranous-labyrinth genes (GJB2, SLC26A4, OTOF, mitochondrial) are good implant performers; spiral-ganglion genes are variable (TMPRSS3) to poor (DDON/TIMM8A). This module walks the reported genotype-outcome correlations and what they mean for counselling.
Sections
Auditory neuropathy — present OAE, absent ABR — looks like the worst implant case, but it depends on the site. About half is caused by OTOF at the inner-hair-cell ribbon synapse, a pre-neural lesion the implant bypasses, so OTOF patients implant well. This module shows why ANSD is no contraindication and why high-risk screening needs automated ABR.
Sections
A genetic result lands in a family, not a textbook. This module covers what a diagnosis adds — recurrence risk, prognosis, a leaner work-up, syndromic surveillance, family cascade testing — alongside cultural humility and the hard ethical question of whether a genotype predicting a poor outcome should affect access, arguing to counsel and plan rather than gatekeep.
Sections
The chapter's forward look: from prognosis today toward cure tomorrow. Why otoferlin (OTOF) became the first inner-ear gene-therapy target — surviving hair cells, a single gene, a pre-neural lesion — with early trials restoring hearing in children, the harder targets beyond it, and why the cochlear implant remains today's treatment while the molecular medicine matures.
Sections
A candidate arrives with one audiometric label — severe-to-profound SNHL — but that label is the end of many different stories. This overview frames the chapter: deafness is a final common pathway, each cause leaves a different mark on the cochlea and nerve, and that mark — not the audiogram — is what the implant works with, so knowing the cause turns a fixed diagnosis into a prediction.
Sections
Before cataloguing causes, a map of where hearing can fail: conductive, sensory (hair cell), neural (spiral ganglion / nerve), or central. 'Sensorineural' fuses the sensory and neural zones — convenient for audiometry, dangerous for prognosis — because the implant injects at the spiral ganglion, bypassing lesions above it and depending on those at or below.
Sections
Where most paediatric implantation starts, and the most time-pressured group of all. Congenital loss affects ~1–2 per 1000 newborns and divides roughly evenly into genetic (Chapter 6) and acquired. This module surveys the acquired half — congenital infection and the perinatal injuries of prematurity, hypoxia, jaundice and sepsis — and frames the group by the developmental clock it races.
Sections
The one cause that changes the clock. Bacterial meningitis spreads to the inner ear, kills hair cells and neurons, and triggers labyrinthitis ossificans — fibrosis then new bone that fills the cochlea from the basal turn and can make insertion impossible. New bone also tracks with neuronal loss, so it warns of a poorer substrate too. Post-meningitic deafness is an otological emergency.
Sections
A baby can be born already deafened by an infection met in the womb. Rubella once did this on an epidemic scale; today CMV is the leading non-genetic cause of childhood SNHL. CMV's defining feature is a progressive, delayed-onset loss that a normal newborn screen does not exclude — making it a process to watch, with surveillance audiology, early diagnosis, and antiviral treatment.
Sections
Deafness that is iatrogenic — caused by the drugs that save lives. Aminoglycosides and cisplatin kill outer hair cells from the cochlear base upward (high-frequency-first, permanent); loop diuretics hit the stria and are often reversible but synergistic. The mitochondrial m.1555A>G variant makes one aminoglycoside dose catastrophic. Because it spares the ganglion early, ototoxic loss implants well.
Sections
The great preventable cause, and a model of where cochlear damage begins: the classic 4-kHz audiometric notch from basal outer-hair-cell injury, and the hidden cost of cochlear synaptopathy — permanent loss of auditory-nerve synapses even when thresholds recover. Noise alone rarely makes an implant candidate, but it shows how the neural substrate can be quietly depleted unseen.
Sections
The quiet giant — the commonest cause of hearing loss, the driver of the ageing burden, and a leading modifiable dementia risk. But 'presbycusis' is several diseases: Schuknecht's sensory, neural, strial and cochlear-conductive subtypes, each with its own audiogram. The neural subtype — spiral-ganglion loss — most undermines the implant substrate and explains variable elderly outcomes.
Sections
Two causes defined by their tempo and their treatability. Sudden SNHL drops over hours-to-days — an emergency with a narrow steroid window. Autoimmune inner-ear disease climbs over weeks-to-months, often bilateral and fluctuating, and is characteristically steroid-responsive. Both are mistakes to miss: one because the window is short, the other because it is rare and treatable.
Sections
Two adult causes with implant-relevant quirks. Ménière's disease (endolymphatic hydrops) gives a fluctuating low-frequency loss and vertigo that complicate candidacy but usually spare the ganglion. Cochlear otosclerosis lays down abnormal otic-capsule bone that can progress to far-advanced loss and, at surgery, conducts current to the facial nerve — a programming and imaging challenge.
Sections
Everything the chapter claims about substrate rests on the microscope. Human temporal-bone archives (Schuknecht, Nadol) show spiral-ganglion survival varies systematically with the cause of deafness — higher for aminoglycoside and hereditary-cochlear loss, lower after meningitis and primary neural disease. The honest limit: the living patient's neurons cannot be counted, only inferred.
Sections
The chapter's payoff turned into a habit of thought. Every cause leaves a signature that governs three things the team cares about: the substrate the electrode finds, the surgery and its timing, and the expectations to set. Read that way, the cause is the opening move of the work-up — a cause→substrate→plan crosswalk, and the bridge into candidacy and evaluation.
Sections
An implant does not repair the ear. It bypasses the hair cells and speaks to the auditory nerve directly, and that single shortcut changes what the brain receives. This chapter is the perceptual science beneath every coding choice.
Sections
Natural hearing owes its richness to an active, nonlinear cochlea: instantaneous compression, razor-sharp tuning and a vast dynamic range. Electric stimulation throws a far cruder switch. This module frames exactly what the implant cannot recreate, and why.
Sections
Acoustic hearing spans about 120 dB from a whisper to discomfort. On a single electrode the entire usable range, from threshold to maximum comfort, can be only a handful of decibels. This is the constraint every implant processor is built around.
Sections
In electric hearing the climb from just-detectable to too-loud spans only a few decibels of current, not eighty. Understanding this steep loudness-growth function is the key to setting comfortable levels and balancing loudness across the array.
Sections
A healthy cochlea instantaneously compresses a hundred-decibel world into the nerve's working range. The implant has lost that gift, so the sound processor rebuilds it with gain control and a mapping function that squeezes wide acoustic input into a few electric decibels.
Sections
Before any sound can be coded it must first be detected. Electric threshold is governed by charge, pulse timing, stimulation mode and integration over time, and the same physics explains how clinicians set the lowest map levels.
Sections
The implant strips speech down to its slowly changing loudness contour. This module shows how well electric hearing tracks that envelope, where temporal acuity is surprisingly good, and where it collapses.
Sections
Change how fast you pulse an electrode and the pitch rises, but only up to a point. This module explains temporal pitch, why it saturates near 300 Hz, and what that ceiling costs the listener.
Sections
Move stimulation toward the base of the cochlea and the pitch rises. This module covers place pitch, electrode discrimination, the frequency-to-place mismatch of real implants, and how place and rate pitch combine and collide.
Sections
Every electrode contact bathes a broad swath of cochlea in current, so the crisp tonotopic map of acoustic hearing is replaced by overlapping, smeared frequency channels. This module explains why and how we measure it.
Sections
Electrodes are meant to be independent voices, but overlapping fields and neural after-effects make them interfere. This module covers how channel interaction arises, how we measure it, and the focusing tricks that fight it.
Sections
Modern arrays carry 12 to 22 contacts, yet most recipients extract only about eight independent streams of information. This module explains the gap, the vocoder evidence behind it, and what it means for design.
Sections
An implant user can ace a word list in a silent booth and then lose the thread of dinner conversation. This module explains how coarse spectral resolution, lost fine structure and channel interaction conspire to make noise the central challenge of electric hearing.
Sections
Many implant users understand speech well yet describe music as noise, beeping or a marching drum. This module is the perceptual why beneath the music chapter: weak place pitch, a rate-pitch ceiling near 300 Hz, and impoverished timbre, with rhythm the one survivor.
Sections
The psychophysical toolbox is not academic decoration: spread-of-excitation, tuning curves, spectral-ripple and modulation tests and loudness scaling each measure a specific limit, and each points to a specific fix in coding, fitting and device choice.
Sections
A cochlear implant must stand in for thousands of hair cells using a dozen or so electrodes. Between microphone and nerve sits the sound processor, whose job is to turn sound into electrical pulses the brain can learn to hear. This overview frames the chapter's hard question — when you can keep only a fraction of the signal, which fraction? — and its past–present–future arc from CIS to today's strategies to the frontier.
Sections
To imitate the ear, be clear about what it does: frequency analysis (the place code), intensity compression, the temporal envelope, and temporal fine structure. The implant recreates envelope and coarse place well and fine structure poorly — which is exactly why speech in quiet is easy and pitch, music and noise are hard. This module sets up the scorecard every strategy is judged against.
Sections
Before the individual strategies, see the whole assembly line. Every implant moves sound through the same sequence: microphone → pre-processing → filter bank → envelope detection → compression/mapping → interleaved pulsatile stimulation. This module lays out that block diagram so each later module — the filter bank, the envelope, the coding strategy — has a clear place in the chain.
Sections
The cochlea's first trick is to be a frequency analyser, laying sound out by pitch along its length. The implant copies this with a bank of filters and one rule: route each frequency band to the electrode at the matching tonotopic place. This module covers how the filter bank rebuilds the place code — the primary pitch cue — and what happens when the map and the anatomy disagree (frequency-to-place mismatch).
Sections
The boldest move in implant coding: from each band keep only the slow amplitude envelope and discard the fast fine structure — the channel-vocoder idea. It works astonishingly well for speech, as Shannon proved with sentences understood from a few bands' envelopes. But the discarded fine structure is where pitch and music live, so the same bargain that makes speech easy makes music hard.
Sections
The past in 'past, present and future' — the moment coding turned a promising device into a working one. Driving electrodes simultaneously let their fields collide and blur the channels; continuous interleaved sampling delivered brief pulses one at a time, so no two fields overlap. The speech gain was large and immediate (Wilson et al., 1991), achieved with the same electrodes — the template most modern strategies still build on.
Sections
If one fact explains why implants fall short of normal hearing, it is this: an electrode's current spreads along the cochlea, so neighbouring electrodes excite overlapping nerve and stop being independent. Listeners behave as if they have only seven or eight effective channels however many electrodes are active (Friesen et al.) — fewer in noise. Channel interaction is the ceiling every strategy fights.
Sections
The strategies most used today take a different tack from CIS: analyse sound into many bands but, each cycle, stimulate only the few carrying the most energy — the spectral peaks. This n-of-m approach concentrates the limited stimulation where the information is and sidesteps some channel interaction. SPEAK pioneered it; its faster descendant ACE became the default in Nucleus devices and one of the most-used strategies in the world.
Sections
Envelope coding stripped out the fast detail that carries pitch; fine-structure coding tries to put some back. MED-EL's FSP family delivers timing-locked pulses on the apical, low-frequency channels, where surviving nerve can still phase-lock to the waveform. The goal is better pitch and music; the benefit is real but modest, and confined to the low frequencies where the nerve's timing precision survives.
Sections
Channel interaction comes from current spreading too widely, so the response is to control the current's shape. Current focusing (tripolar) narrows a single electrode's field for a sharper channel; current steering drives two electrodes together to place a percept between them — a virtual channel the array does not physically have. One makes each channel cleaner, the other makes more of them; both carry costs in power and uncertain benefit.
Sections
Not all of the implant's intelligence is in the coding strategy — much sits earlier, in the front end. Automatic gain control fits the wide real-world range into the processor's narrow input; directional microphones and noise reduction raise the signal-to-noise ratio of what reaches the coder. Because buried speech cannot be recovered downstream, this is where much of the modern progress in hearing-in-noise has been won.
Sections
The 'future' the title promised. Coding has come far, but the gap to normal hearing is wide: fine pitch, music and effortless conversation in noise are still unsolved. Advances come on three timescales — near-term deep-learning software, a mid-term tighter electrode–neuron interface, and the far-horizon promise of optical stimulation that could finally break the channel ceiling. This closing module looks ahead, honestly.
Sections
The goal of treating hearing loss is clarity, not just loudness. Hearing aids are the right first step, but the impaired cochlea sets boundaries even the finest aid cannot cross, and many people abandon aids citing too little benefit. This overview frames the chapter: the functional correlates of SNHL that the audiogram never shows, why audible is not intelligible, and where the answer becomes a cochlear implant.
Sections
The audiogram is the most useful test in audiology and the worst guide to whether a hearing aid will satisfy. It measures one thing — detection thresholds — and is silent about the suprathreshold correlates (recruitment, frequency and temporal resolution, dead regions, distortion) that decide intelligibility. This module draws the distinction the chapter depends on: audible is not the same as intelligible.
Sections
Before cataloguing what a hearing aid cannot do, be clear about what it does well: restore audibility. Prescriptive formulas, frequency lowering, extended high-frequency response and compression all lift soft, high-frequency speech back above threshold, and audibility strongly predicts aided speech — with telling exceptions (auditory neuropathy, central loss). But audibility has a ceiling, and beyond it lies the rest of the chapter.
Sections
If one phenomenon explains why a severely impaired ear is hard to aid, it is loudness recruitment. Sensorineural loss raises the threshold while the discomfort ceiling stays put, so the usable window collapses (Boothroyd: ~25 dB at 90 dB loss) and the ~40 dB span of speech no longer fits. Within that narrowed range loudness grows explosively — soft is inaudible, a little louder is intolerable — worst where consonants live.
Sections
Recruitment follows directly from how the cochlea normally controls loudness. Outer-hair-cell damage abolishes the active compression and sharp tuning, so the nerve-fibre tuning curves broaden and lose their tips; a rising stimulus rapidly recruits fibres in the tails and neural response surges — heard as abnormally fast loudness growth. The same logic explains why electrical hearing, with its linear neural response, has no recruitment.
Sections
Another distortion amplification cannot fix: lost frequency selectivity. The same outer-hair-cell damage that abolishes compression broadens the cochlea's auditory filters, smearing adjacent formant peaks so the spectral pattern that distinguishes vowels is blurred. A hearing aid changes level, not filter width, and attempts to pre-sharpen the spectrum fail because the broadened cochlea re-smears it.
Sections
Speech unfolds in time, and the ear must follow it on a millisecond scale — the gaps between words, the dips in noise through which a listener glimpses a target. The impaired ear integrates over a longer window and smears these details. This temporal blurring is least obvious in quiet and most punishing in noise and reverberation, and amplification cannot restore the lost timing.
Sections
Some of the most frustrating hearing-aid failures come from a cochlear dead region — a stretch with no functioning inner hair cells or neurons. The audiogram may still show thresholds (off-frequency detection), luring the clinician into amplifying frequencies that can never be properly heard. Doing so does no good and can hurt (Vickers). Dead regions are a hidden reason aids fail — and a pointer toward an implant.
Sections
This module pulls the deficits into one accounting: aided understanding is an audibility component plus a distortion component. For mild loss, audibility-based models (the Speech Intelligibility Index) work; as loss deepens, the distortion penalty grows until speech is fully audible yet still poorly understood, and making it louder buys nothing. That widening gap between audible and intelligible is why amplification fails.
Sections
All the deficits converge on one judgement: has this hearing aid done everything a hearing aid can do? It cannot be read from the audiogram — it is answered by aided speech testing and by what the patient reports. Many reject aids for insufficient benefit. When aided performance falls below what an implant reliably delivers, the patient has crossed the candidacy line, and the conversation turns to implantation.
Sections
The smooth aid-then-implant story assumes ordinary outer-hair-cell loss; where the lesion sits can overturn it. In auditory neuropathy the hair cells may work yet the nerve fires out of step, so aids disappoint and the implant — imposing synchrony — often succeeds. Single-sided deafness has nothing to amplify acoustically. And when the nerve itself is absent or destroyed, neither aid nor implant has a target.
Sections
Every thread of the chapter leads to one resolution. A hearing aid is acoustic — it sends amplified sound through the broken cochlea. A cochlear implant is electrical — it converts sound to current and stimulates the nerve directly, skipping the damaged cochlea entirely. Free of recruitment, with a wider, cleaner range, it succeeds past the crossover where the aid cannot. The implant is the treatment of choice, and the door into candidacy.
Sections
Before anyone decides whether a person should have a cochlear implant, someone has to measure how they hear — and that is never a single number. The evaluation is a battery of complementary tests bound by one idea: the cross-check principle. No result is accepted in isolation; every behavioural finding is checked against an independent objective measure, so that agreement builds confidence and disagreement (auditory neuropathy, non-organic loss) becomes the diagnosis. This chapter is the audiologist's toolkit; the candidacy decision that uses it is the next.
Sections
The audiogram is the most familiar picture in audiology and the most easily taken for granted. Behind each symbol lies a careful bracketing procedure and a chain of calibration that converts the audiometer's dial reading into the sound pressure the cochlea actually receives. Get the technique right and the audiogram anchors the battery; get the calibration wrong, especially in a baby's small ear, and every later target is off. This module covers how a threshold is obtained, why inserts are preferred, what dB HL references, and how the RECD rescues the measurement where it matters most.
Sections
Masking is where audiometry becomes a craft. A tone loud enough to test a poor ear can cross the skull and be heard by the good ear instead, so the threshold recorded may belong to the wrong cochlea. The remedy is to busy the non-test ear with noise — but too little leaves the cross-hearing, and too much spills back and shifts the very threshold being measured. Between those errors lies a plateau of correct masker levels, and finding it is the skill. The whole problem hinges on the interaural attenuation, which is large for insert earphones.
Sections
Air conduction tells you how much a person hears; bone conduction tells you where the problem is. By driving the skull directly, a bone vibrator skips the outer and middle ear and asks the cochlea what it can do alone. The difference — the air–bone gap — separates a conductive blockage, which may be treatable, from a true sensorineural loss, and even hints at the cause, from the Carhart notch of otosclerosis to the deceptive low-frequency gap of a third-window lesion. This module covers measuring and interpreting bone conduction, and the traps that mislead.
Sections
Pure tones tell you what a person can detect; speech tests tell you what they can understand — and understanding is what hearing is for. It begins with the speech reception threshold, which should agree with the pure-tone average and so validates the audiogram, then moves above threshold to ask how many clearly audible words are correctly identified. The way that score behaves at higher levels — whether it holds or rolls over — is a classic pointer beyond the cochlea. This module covers how speech is tested and why material, talker and level decide whether the number means anything.
Sections
Tympanometry is the quiet workhorse of the battery: a few seconds, no cooperation required, and a great deal learned. By varying the pressure in a sealed ear canal and measuring how readily the eardrum accepts sound, it images the middle ear — taut or floppy, air-filled or fluid-filled, normally pressurised or pulled in. Its trace falls into a handful of recognisable shapes, and a single extra number, the ear-canal volume, settles the one ambiguity those shapes leave. It is usually run first, and in the very young it needs one crucial change of probe tone to work at all.
Sections
A loud sound makes a tiny middle-ear muscle contract, and that involuntary twitch — measurable in seconds, with no cooperation — is one of the most informative signs in the battery. Because the reflex runs a long loop from cochlea to brainstem and back along the facial nerve, where it fails tells you where the lesion is. Its threshold rises predictably as cochlear hearing worsens, so a reflex present at a normal level quietly argues against a severe loss. This module covers the reflex as a diagnostic instrument, and points to its electrical cousin used through the implant.
Sections
The cochlea does not merely receive sound — it makes it. The outer hair cells that amplify the travelling wave leak a little energy back out, and a sensitive microphone in the ear canal can record those echoes. Their presence is a near-instant sign that the cochlear amplifier works and the middle ear is clear, which made OAEs the workhorse of newborn screening. But they answer a yes/no question, not a how-much one, and their greatest value comes from a disagreement: emissions present while the brainstem response is absent — the signature of auditory neuropathy.
Sections
When a click reaches the ear, a volley of synchronised activity sweeps up the nerve and through the brainstem, and scalp electrodes catch its wake — a sequence of waves within ten milliseconds, each a signpost of a different station. The auditory brainstem response is tiny and recoverable only by averaging thousands of sweeps, but it asks for no cooperation, which makes it the foundation of testing in babies and the arbiter when behaviour is in doubt. It can estimate threshold, point to a tumour by its fifth wave, and unmask auditory neuropathy through the cochlear microphonic.
Sections
The brainstem response is the workhorse of objective audiometry, but it cannot do everything, and a family of related tests fills its gaps. When the question is whether a profoundly impaired ear has any usable hearing, the steady-state response can be driven louder and resolve a threshold the ABR can only call absent. When the question is whether the inner ear is swollen by hydrops, electrocochleography reads the cochlea's own potentials. And when the question is whether amplified sound reaches the cortex, the slow cortical response can answer. The through-the-implant versions belong to Objective Measures.
Sections
A baby cannot raise a hand to a tone, so paediatric audiometry is the art of reading what a child can do at each stage of development and building a valid threshold from it. The youngest are watched for a flicker of response; a little older, they can be conditioned to turn toward a reward; older still, they drop a block in a bucket on hearing a sound. Choosing the method by developmental — not chronological — age is half the skill; the other half is knowing what the result means, because an infant's response level overstates true threshold and the simplest method reveals only that a child reacted.
Sections
Knowing a child's thresholds is not the same as knowing what they do with sound, and for a deaf child being considered for — or recovering from — an implant, the second question matters most. Paediatric speech testing climbs a ladder from detecting that a sound is present, through telling sounds apart and identifying which was heard, to genuinely comprehending meaning, with the rung chosen by language age. The materials run from a parent's checklist to open-set words and sentences in noise, with closed-set picture tasks in between that must be read against the level of lucky guessing.
Sections
The hardest listening in real life happens in noise, and a test in quiet can completely miss it — a person may ace single words in a silent booth and still be lost at every dinner table. Speech-in-noise testing measures the thing that matters: the signal-to-noise ratio at which understanding holds, found by letting the noise close in adaptively. The details are everything — whether the masker is steady or a babble of voices, where the loudspeakers sit — and a growing movement toward ecological validity argues our tests should look more like life than like the quiet booth.
Sections
Fitting a hearing aid is a prescription, and like any prescription it must be verified against what actually reaches the patient — not what the software predicts. Real-ear measurement does exactly that: a slender probe tube near the eardrum records the true sound pressure the device delivers, and that measured output is matched to an evidence-based target for soft, average and loud speech. It has replaced the older functional-gain method, and it is doubly important in children, whose small ears turn the same setting into far more sound. Above all, verification must come first — so a poor result can be blamed on the ear, not the fitting.
Sections
Threshold is only the floor of hearing; what happens above it can matter just as much. In a damaged cochlea loudness grows abnormally fast, so the comfortable window between the faintest audible sound and the merely tolerable shrinks, and speech can no longer be fitted into it. The same suprathreshold domain holds tinnitus and hyperacusis, documented before any implant, and one of audiology's subtler challenges: the loss the tests cannot quite believe — non-organic hearing loss, where behaviour and the objective measures disagree, and the cross-check exists to catch it.
Sections
A perfect score in a quiet booth and a miserable time at every family gathering can belong to the same person, which is why the evaluation cannot end at the audiometer. Validated questionnaires capture what the tests cannot: how much the loss handicaps daily life, how much benefit an aid or implant delivers, how it changes quality of life, and whether it achieves the goals the patient came in with. Used before and after intervention, and consistently across patients, they turn felt experience into trackable numbers that complement the objective battery and anchor counselling.
Sections
The sound-treated booth and the on-site audiologist are scarce resources, and in much of the world they are the bottleneck between a person with hearing loss and a diagnosis. Tele-audiology is loosening that constraint — testing in real time over a link, storing objective recordings for later expert review, or putting a validated self-test on a phone. At the same time the field is rethinking what a test should measure: not a single number in silence but a profile of real-world benefit, including the effort listening costs. Both movements share one through-line — ecological validity.
Sections
A pile of test results is not a diagnosis. The skill the whole chapter builds toward is synthesis: taking the audiogram, the masked thresholds, the air–bone gap, the speech scores, the tympanogram and reflexes, the emissions and evoked potentials, and fitting them into a single picture that hangs together. When it does, the type, degree, configuration and site of the loss fall out, and so does the judgement that the result is valid. Each site of lesion leaves a recognisable fingerprint, and reading those fingerprints is what turns a technician into a diagnostician — and feeds the candidacy decision.
Sections
This is where the atlas turns clinical. The question becomes practical: should this patient have a cochlear implant? This overview frames candidacy as a multidisciplinary judgement of whether the implant will outperform the best hearing aids, weighed against risk and rehabilitation — the 'tipping point' between candidacy and non-candidacy, and the roadmap from the first audiogram to the decision.
Sections
Who counts as a candidate has changed more in forty years than almost anything in the field. From the totally deaf adult of the early 1980s, every revision loosened the criteria: the audiometric bar fell, the allowable aided-speech ceiling rose toward 50–60%, and the field shifted from hearing sensitivity to functional hearing. A patient who 'wouldn't have qualified' a decade ago may qualify today.
Sections
Candidacy is established in the sound booth. The battery characterises the loss, confirms what amplification restores, and — decisively — measures best-aided sentence recognition. The speech is recorded (removing lip-reading and rate cues) and presented at conversational and softer levels, with the patient's own optimally-fitted aids, so the score reflects real-world understanding and is comparable across clinics.
Sections
Candidacy comes down to numbers that reward careful reading. The degree of loss sets the scene; the decisive figure is the best-aided sentence score, which must fall below a criterion that crept toward 50–60%. A subtlety underpins it: scores rise steeply with presentation level, so candidacy tests at conversational/soft levels that reflect real life, not loud ones that flatter — and the line is shaped by device labelling, funding rules and which ear is tested.
Sections
Real listening happens in noise, and candidacy testing has had to follow. A word test in quiet flatters a good aid user to the ceiling and crushes a poor one to the floor; the modern battery adds adaptive sentence-in-noise tests. But noise testing hands the examiner power: by choosing the SNR or separating the loudspeakers so directional mics help, a clinician can engineer almost any score — so the choice of test condition is an ethical question, answered by a single fixed protocol applied identically to every candidate.
Sections
A patient can be a perfect clinical candidate and still not get an implant, because candidacy runs through a second machinery of regulators and payers. The FDA regulates manufacturers and their labels — guidance, not mandate — so off-label implantation is legal; but off-label cases are not reimbursable under CMS-regulated plans, so money is the real limit. CMS applies its own criterion, and looser CE-marked labels open doors the US tables keep shut. The same patient can qualify under one device or payer and fail under another.
Sections
Candidacy is also about what to expect afterwards. Two pre-operative facts predict most of what can be predicted: a shorter duration of deafness and a higher pre-implant word score, both reflecting an intact auditory foundation. Age, aetiology, ear and device matter less, and much of the outcome stays unexplained — which is why candidacy counsels in probabilities, never promises.
Sections
A single audiometric cut-off treats every ear at the threshold as identical when their prospects are not. The actuarial model reframes candidacy as the per-ear odds that an ear will understand more with an implant than with its aid — the UK group combining pre-op score and duration of deafness and implanting at about four-in-five odds, the Melbourne group reaching a parallel rule. Because they are computed per ear, two ears with identical hearing can differ, and the maths makes explicit why implanting the poorer or shorter-deaf ear is often right.
Sections
Hearing decides whether an implant is worth doing; the medical and otologic assessment decides whether it can be done safely and used successfully. Active ear disease is treated first; aetiology flags issues (ossification, malformation, a deficient nerve) that change the plan; fitness for anaesthesia is confirmed; meningitis vaccination is arranged; and readiness for programming and rehabilitation is checked.
Sections
Imaging is the third tier of the candidacy work-up. High-resolution CT shows the bony cochlea (patency, ossification, malformation); MRI shows the fluid, the cochlear nerve, and excludes retrocochlear disease. Most findings change how the surgery is done; only a deficient or absent cochlear nerve usually changes whether to implant — a candidacy-focused preview of the imaging chapter.
Sections
The inner ear is an organ of balance as well as hearing, and implantation puts that balance at risk. The candidacy work-up includes a focused look at vestibular function — not to exclude patients but to shape which ear is implanted. If the two labyrinths differ, the surgeon would rather implant the already-weaker one and spare the better balancer; if the other side is already dead, implanting the only balance organ can be disabling. Because no single test declares a labyrinth dead, candidacy combines several into a multifrequency picture like an audiogram.
Sections
A baby cannot tell you whether the aid helps. Paediatric candidacy leans on objective measures, a fitted hearing-aid trial watched for acceptance and developing skills, and auditory/language/developmental assessment — all under the urgency of the sensitive period. When amplification is not enough, the answer in a child is to implant early; candidacy and timing become almost the same question.
Sections
The clearest sign of how far implantation has come is the list of people who now qualify and once did not: those with useful residual hearing, good low-frequency hearing suited to electric-acoustic stimulation, single-sided and asymmetric deafness, and auditory neuropathy. Each expansion follows the same logic — implant wherever a hearing aid cannot deliver enough — and the boundary keeps moving outward.
Sections
The fastest-growing group of candidates is the oldest, and they are the most often wrongly turned away. Older recipients achieve outcomes close to younger ones and tolerate surgery well; anaesthetic risk follows physical-status class, not birthdays. And the hearing–brain relationship cuts the other way from the usual worry — because hearing loss is linked to cognitive decline and dementia, withholding an implant may do harm rather than avoid it. The main barrier is not the patient but the referral that never happens.
Sections
Whether an implant is used and valued depends on far more than the audiogram. Candidates carry higher rates of depression and isolation, which implantation tends to improve; but the device only helps those who wear it and work with it, and the commonest reason it goes unused is a mismatch between hope and reality. Managing expectations, recognising support needs, and respecting the cultural and ethical weight of the decision are part of candidacy.
Sections
Most people who would benefit from a cochlear implant never get one — not mainly because of strict criteria, but because of access. Of the large severe-to-profound population, only a small fraction are referred, assessed and implanted, lost to low awareness, the wrong assessment materials and quiet under-referral. Capped funding adds a 'most obvious candidate' rationing bias that squeezes out borderline patients who would still gain. None of this is justified by the economics, which are strongly favourable.
Sections
Candidacy is not only a calculation of benefit; it is a conversation, and an ethical one. The work-up weighs the cultural meaning of deafness — most acutely for a deaf child of Deaf parents — and the patient's own motives and understanding. As candidacy expands into people with learning disability, dementia or multiple disabilities, the routine matter of consent becomes real clinical work. And because the device only helps those who use it, honest counselling about what implantation can and cannot deliver is part of valid consent.
Sections
Once a patient is a candidate, two questions remain: which ear, and how many. The poorer ear is often favoured — outcomes are statistically similar and the better ear is preserved — though a long-dead or malformed ear may favour the better side. A second implant restores binaural hearing (localisation, speech in noise), while a bimodal implant-plus-aid adds low-frequency acoustic detail.
Sections
Hearing with two ears is not simply twice one ear: comparing the inputs to the two sides is how the brain locates sound and pulls speech out of noise, which makes the second ear its own candidacy question. The biology is time-sensitive — prolonged monaural stimulation inhibits the deprived pathway — so the second implant should follow soon, before the binaural window narrows, and it also buys insurance against device failure. The alternative is bimodal hearing, trading some binaural development for preserved acoustic detail.
Sections
Every thread of the chapter ties together into a single judgement. No one test decides candidacy; the audiological, medical, imaging, language, psychological and developmental assessments are assembled in tiers and brought to a team meeting. A careful team sometimes concludes the answer is no. When it is yes, candidacy hands the patient on to the surgery, device choice and programming the rest of the atlas describes.
Sections
Preoperative imaging both finishes candidacy and plans the operation, yet there is no settled consensus on which scan to do, for whom, or in what order. This chapter is built around an MRI-predominant, selective-HRCT protocol developed in a prospective study, structured by two checklists — the MRI fishbone and the HRCT inside-out. It is the philosophy the rest of the chapter applies, structure by structure.
Sections
Once a patient is judged a candidate, imaging turns the decision into a plan. A CT and an MRI of the temporal bone answer two questions at once — is there a cochlea to implant and a nerve to drive, and what anatomy will the surgeon meet? The two modalities are complementary, CT reading bone and MRI reading fluid and nerve. A sequence of three questions keeps the work-up in order, and a few findings act as absolute gates that turn a cochlear implant into an auditory brainstem implant.
Sections
A temporal-bone CT is acquired and displayed in ways specific to the tiny dense structures it must resolve. Thin sections and a bone algorithm sharpen the otic capsule; near-isotropic voxels let one axial scan reformat into any plane. The axial plane is not true horizontal but tilted along the lateral semicircular canal, and the image is read on a wide bone window that makes dense detail leap out while flattening soft tissue — and that contrast choice defines exactly where MRI must take over.
Sections
If CT is the map of the bone, MRI is the map of what lives inside it. With heavily-T2 sequences the fluid labyrinth lights up like a luminous cast, the nerves stand out as dark threads, and early fibrosis shows as a quiet loss of signal before CT sees anything. The most important view is a thin oblique-sagittal slice across the internal auditory canal, laying the four nerves out face-on so the cochlear nerve can be measured — the check that decides whether there is a nerve to stimulate at all.
Sections
You cannot recognise an abnormal cochlea until you can read a normal one. On CT the bone window draws the otic capsule, the cochlear turns around the modiolus, the vestibule and canals, the windows and facial canal; on T2 MRI the same structures appear as bright fluid against dark bone. The internal auditory canal has a normal size worth memorising, and all of this anatomy is best learned through the embryology that produced it — because the malformations to come are simply development stopped at successive stages.
Sections
A malformed inner ear is development frozen at a moment in time, and reading it is recognising which moment. The further back the arrest, the more is missing — from the Michel deformity with no labyrinth, through a common cavity, to a small or incompletely partitioned but entirely implantable cochlea. A succession of classifications turns the spectrum into named categories that predict candidacy, electrode choice and gusher risk. The crucial fork is between the few forms that mean an auditory brainstem implant and the many that simply change the surgical plan.
Sections
Among the implantable malformations, the incomplete partitions and the enlarged vestibular aqueduct carry a specific hazard: the perilymph gusher. The distinction turns on two features — whether the modiolus is present and whether the interscalar septa are formed — which sort the cochlea into hypoplasia or incomplete partition types I, II and III, each with its own gusher risk, from a mild ooze to a torrent that can sweep the electrode into the internal auditory canal. The enlarged vestibular aqueduct, measured against three criteria and linked to Pendred syndrome, completes the picture.
Sections
Everything else assumes there is a nerve for the implant to stimulate — and this is where that assumption is tested. The single most important teaching point is a trap: the bony internal auditory canal can look perfectly normal on CT while the cochlear nerve inside is hypoplastic or absent, so a child with profound loss needs MRI. Where the nerve is merely small, the prognosis is guarded; where it is truly absent, the implant has no target and the decision turns to an auditory brainstem implant. And the nerve's calibre hints at how many neurons survive.
Sections
Meningitis can fill the channel the electrode must enter with first fibrous tissue and then bone, on a clock that races the surgeon. The earliest fibrous stage is invisible to CT — there is no bone yet — but shows on MRI as a loss of the bright fluid signal, which is why a normal CT can falsely reassure. Where the bone has spread, a patency grade translates directly into a surgical manoeuvre, from a normal cochleostomy through a drill-out to a split array. The right response is almost never exclusion; it is to implant early.
Sections
The facial nerve is the surgeon's constant companion and hazard. The transmastoid approach to the round window threads the facial recess in the immediate shadow of the nerve, so the operation begins with the CT tracing the fallopian canal segment by segment. In a malformed ear the nerve is far more likely to wander, and even in a normal ear its tympanic segment may be dehiscent. Imaging also looks ahead: where the apical turn and otospongiotic bone sit close to the nerve, electrodes can stimulate it.
Sections
The cochlea is the destination, but the surgeon has to get there, and imaging maps the route. The transmastoid facial-recess approach runs through a corridor whose width depends on mastoid pneumatisation and recess depth — and which can be crowded by a wayward vessel: a high jugular bulb over the round window, an anterior sigmoid sinus, an aberrant carotid near the basal turn. Chronic ear disease, a previous cavity or a fracture can rewrite the landmarks entirely. This is the field the surgeon will work in.
Sections
Here radiology stops describing and starts ordering. The cochlea is not one size, and the electrode must match it: a short duct or a cochlea without a modiolus calls for one kind of array, a normal cochlea with an intact modiolus for another. Measured on the scan — duct length, basal-turn diameter, modiolar integrity — these numbers choose the array family, estimate how deep it will wind, and feed straight into the device order and the surgical plan. This is the bridge from the picture to the implant.
Sections
Imaging a child carries extra weight in both directions. It must not miss a cochlear-nerve deficiency a normal CT would conceal, which is why MRI is non-negotiable in a child with profound loss — even at the cost of a general anaesthetic. But the developing lens is exquisitely radiosensitive, so temporal-bone CT is held to ALARA. Two further questions recur — does the implant outgrow the child, and is the small temporal bone ready? — and serial studies reassure that the electrode does not migrate as the skull grows.
Sections
Most insertions are confirmed afterwards by the implant's own objective measures, but some need to be watched as they happen. When the evoked responses are unreliable — a malformed or ossified cochlea, a revision, a suspected misplacement or tip fold-over — intra-operative plain film or real-time C-arm fluoroscopy lets the surgeon see the array going in and correct it on the spot, most valuably in the malformed ear where it can stray out of the cochlea entirely. Used with discipline, the radiation cost is small.
Sections
The operation ends with a question imaging must answer: where did the electrode end up? A good array reads as a smooth, evenly-spaced spiral in scala tympani, but two complications hide in the detail — the electrode slipping into scala vestibuli, and the tip doubling back — both judged against the lamina spiralis ossea. A plain film confirms it if the projection aligns to the cochlea's tilted axis; counting the rings needs to know the device. For finer detail, cone-beam and high-speed flat-detector CT now give low-dose pictures of scalar position.
Sections
A cochlear implant is metal with a magnet in the skull, so for years it was an absolute bar to MRI — a problem for a patient who later needs to image the brain or the other ear. That has changed: conditional scanning is now routine at 1.5 T provided the rules are followed. The chief hazards are the magnet twisting or demagnetising and local heating, and the chief inconvenience is a large signal void over the nearby skull base. Crucially, because the artefact is local, the opposite side can still be followed.
Sections
The radiology of cochlear implantation is not standing still, and its frontier is shifting the central question. Where conventional imaging asks whether the anatomy is implantable, the newer tools ask whether the neural pathway is functionally viable and where. Cone-beam and high-speed flat-detector CT sharpen the structural picture at lower dose; navigation and robotics promise more precise insertion; and diffusion tractography and functional MRI begin to map the pathway and its cortical processing. Most remain research tools, but they sketch where the work-up is going.
Sections
Everything in this chapter exists to be written down in one place, for one ear at a time, so nothing surgical is missed. A structured, side-specific report walks the surgeon's path: the mastoid and its vessels, the facial nerve, the cochlear turns and modiolus, the patency and duct length, the malformations and the vestibular aqueduct, and — from the MRI — the cochlear nerve. But a list of findings is not yet useful; the report ends with an actionable summary that names the implantable side, the hazards, the array, and whether to implant at all — closing the loop to candidacy and surgery.
Sections
Before any electrode meets any nerve, sound must cross a barrier that no wire penetrates: intact skin. This opening module tours the cochlear implant as a two-part machine — an external sound processor and an internal receiver-stimulator — coupled only by a pair of magnets and an inductive radio link. Naming every component now gives us a shared vocabulary for the rest of the chapter.
Sections
A cochlear implant is a relay race in roughly seven stages, handing an acoustic signal from a microphone to a tonotopic sector of the auditory nerve. Walking the path stage by stage reveals exactly where the hardware ends and the coding algorithm begins — and why high frequencies end up at the base while low frequencies travel to the apex.
Sections
One inductive radio link carries everything across the skin — power, stimulus commands, and (in most systems) measurements coming back the other way. Understanding forward versus back telemetry explains how a surgeon confirms the device works before closing, and why coil alignment over the magnet is not a cosmetic detail.
Sections
The Cochlear Nucleus line is the original multichannel implant and the world's most-implanted, born from Graeme Clark's Melbourne work. This module decodes its receiver-stimulator lineage, the parallel processor generations, and the elegant model-number convention in which one digit names the platform and another names the array.
Sections
Within a single manufacturer, Cochlear offers the cleanest illustration of the central electrode trade-off: hug the modiolus for efficiency, or ride the lateral wall for atraumatic depth. The Contour Advance, Slim Straight, Slim Modiolar and Hybrid L24 map that trade-off onto four concrete arrays — and onto the 'inside track' geometry that lets a shorter array reach the same angular depth.
Sections
Advanced Bionics built its identity on a hardware idea: give every one of 16 electrodes its own independent current source. That architecture is the substrate for current steering — balancing charge between two adjacent contacts to conjure 'virtual channels' at pitches between the physical electrodes, up to 120 spectral bands across the array.
Sections
Advanced Bionics offers three 16-contact array geometries — Mid-Scala, SlimJ and 1J — plus the retired Helix and the cautionary tale of the Silastic positioner. Pairing them with the Phonak-derived Naida and Marvel processors completes the AB system from cochlea to Bluetooth.
Sections
MED-EL took the opposite design bet from perimodiolar makers: build a long, soft, straight array that lies against the lateral wall and reaches deep into the cochlea, prioritising atraumatic insertion and full tonotopic coverage over modiolar proximity. The FLEX tip, the fixed 12-channel architecture, and the FLEX length ladder all follow from that one philosophy.
Sections
Beyond its arrays, MED-EL is known for two things: a rotatable MRI magnet that ended the era of magnet-removal surgery, and fine-structure coding strategies that hand temporal timing — not just envelopes — to the apical channels. SONNET behind-the-ear and RONDO single-unit processors complete the system, with the Oticon Medical/Neurelec lineage as a historical footnote.
Sections
An electrode array is a physical ruler laid against a frequency map that varies by up to 40% from one person to the next. This module connects array length, insertion angle and an individual's cochlear duct length to the spiral-ganglion neurons each contact actually stimulates — and to the place-pitch mismatch that follows when a one-size-fits-all frequency table meets a one-of-a-kind cochlea.
Sections
It is one of the most humbling facts in the field: a 22-electrode implant typically delivers the functional resolution of only four to eight independent channels. The culprit is overlapping current spread in the conductive perilymph, and the cure — narrowing the field — trades focality against threshold. This module is the biophysical hinge of the chapter.
Sections
Every intracochlear array can be placed into one of three families by where it is engineered to rest in the scala-tympani cross-section. The Advanced Bionics HiFocus trio — 1J, Helix and Mid-Scala — happens to span all three within one manufacturer, making it the canonical comparison for the modiolar-proximity-versus-atraumaticity trade-off.
Sections
Once an array is placed, the clinician chooses how current flows: out to a distant ground, between two intracochlear contacts, or focused by flanking returns. Each configuration sits on a continuum trading threshold against selectivity, quantified by classic spatial-tuning data — and underpinned by the charge-balanced biphasic pulse that protects the tissue from every one of those modes.
Sections
The acoustic world spans roughly 100 dB; a cochlear implant must squeeze it into an electrical window often only about 20 dB wide, bounded by a barely-audible threshold and an uncomfortably loud ceiling. How wide that window is, and how steeply loudness grows within it, depends substantially on how far each contact sits from the neurons — the device-level rationale for perimodiolar design.
Sections
An implant must survive decades in a warm saline environment, be reported on with an honest reliability metric, and still let its recipient be scanned. This module covers what the device is made of and why, how cumulative survival rate is computed and categorised, and the angle rule and artefact sizes that govern MRI in implant recipients.
Sections
Some candidates still hear low frequencies well; electric-acoustic stimulation refuses to throw that away. By placing a short, soft array in the basal turn for high-frequency electric hearing while amplifying the preserved apical acoustic hearing, EAS combines a hearing aid and a cochlear implant in one ear — provided soft-surgery technique keeps the cochlea intact.
Sections
Not every cochlea is patent or normally formed. Ossification after meningitis can wall off the lumen; malformations can erase the modiolus entirely. This module follows the surgeon's tiered escalation through ossified cochleae and the Sennaroglu malformation spectrum to the auditory brainstem implant, where the array leaves the cochlea behind altogether.
Sections
Most of this chapter follows the three manufacturers that share the bulk of the world market, but the device landscape is wider. Behind it lie the pioneer electrodes that started everything — House's single channel and the Utah Ineraid's six percutaneous contacts — and beside it sit present-day makers in France, China and Korea: Oticon Medical (now divested to Cochlear), Nurotron, LISTENT and TODOC, several built explicitly to make the operation affordable to far more of the world.
Sections
A master, filterable and sortable reference comparing every cochlear-implant system available today — Cochlear, Advanced Bionics and MED-EL, the recently divested Oticon Medical line, and the emerging Nurotron, LISTENT and TODOC systems — across implant and array, sound processors, MRI and build, and what makes each distinct. Specs and features only; no head-to-head performance claims.
Sections
The implant of the next decade aims to disappear — burying the microphone and battery inside the body — and to replace broad electrical current spread with tightly focused light. This closing module surveys the engineering frontier and then steps back to the practical question every clinician faces: given this anatomy and these goals, which device do you choose?
Sections
Every cochlear-implant sound-coding strategy exists because the previous one hit a wall. This opening module lays out the genealogy as one branching family tree — single-channel to waveform to feature-extraction to n-of-m to fine-structure/current-steering to present synthesis to future — and establishes the two engineering axes (waveform vs envelope, all-channels vs peak-picked) that organise everything that follows.
Sections
The first commercial cochlear implants used a single intracochlear electrode and a single processing channel. This module dissects the 3M/House signal chain, shows why one channel cannot exploit the cochlea's tonotopic map, and frames the leap to multichannel place coding as the field's first great supersession.
Sections
Compressed Analog (CA) split the speech waveform into a handful of contiguous bands and delivered the filtered analog signals simultaneously and continuously to corresponding electrodes. It outperformed single-channel devices but introduced a fatal flaw — simultaneous stimulation sums electric fields, the channel-interaction problem that CIS would solve.
Sections
Continuous Interleaved Sampling (CIS) extracts each band's envelope and uses it to modulate temporally staggered, non-overlapping biphasic pulse trains — so no two electrodes ever fire at once. By eliminating field summation, CIS became the foundation on which nearly every modern strategy is built.
Sections
Before spectral-maxima strategies, the Melbourne/Nucleus team tried to explicitly extract the perceptually important features of speech. The first feature-extraction processor tracked the fundamental frequency F0 and the second formant F2 using zero-crossing detectors — a fundamentally different philosophy from waveform strategies.
Sections
The next Nucleus feature-extraction processor added the first formant F1 to recover low-frequency vowel information, splitting the electrode array into apical (F1) and basal (F2) stimulation sets. It improved speech recognition but exposed the limits of formant tracking for consonants.
Sections
Multipeak was the high-water mark of the feature-extraction era. It kept F0/F1/F2 formant tracking but bolted on three fixed high-frequency band-pass filters to recover consonant cues. It improved consonant identification — yet its formant-extraction errors in noise foretold the end of the feature-extraction philosophy.
Sections
The Spectral Maxima Sound Processor abandoned explicit feature extraction entirely. It analysed the spectrum with a 16-filter bank and transmitted only the six largest spectral maxima — no F0, no F1, no formant tracking. This data-driven 6-of-16 design is the bridge between the feature-extraction era and the modern n-of-m family.
Sections
The n-of-m idea — filter into m bands, stimulate only the n with the largest envelopes — became the backbone of Cochlear's strategies. SPEAK refined it with an adaptive number of selected channels, but its low stimulation rate, forced by the slow Nucleus 22 link, set up the move to ACE.
Sections
The Advanced Combination Encoder fused SPEAK-style spectral-peak selection with CIS-style high-rate non-overlapping pulses, becoming the default strategy of the Nucleus system. ACE is the present-day commercial synthesis of the n-of-m lineage — and a useful baseline for understanding what comes after it.
Sections
Envelope strategies throw away the fast temporal fine structure within each band — the very cues that carry pitch, melody and tonal-language information. MED-EL's fine-structure strategies phase-lock the apical channels to that fine structure, but the electric temporal-pitch ceiling near 300 Hz caps how much benefit is possible.
Sections
With only ~22 physical contacts, can an implant create spectral detail between them? Current steering shares current across adjacent electrode pairs to synthesise virtual channels, while current focusing sharpens the field to reduce channel interaction. Both push at the spatial limits of electric hearing — with mixed clinical payoff.
Sections
Today's commercial strategies each preserve a different extra cue on top of the shared CIS/n-of-m foundation. This module synthesises the present landscape — ACE and PACE, MED-EL high-rate CIS and FS4, Advanced Bionics HiRes/F120, Oticon Medical's pulse-width-coding Crystalis, and Nurotron's APS/Symphony — and explains why incremental gains have plateaued.
Sections
The lineage does not end with ACE and FS4. The next leap reframes coding itself: end-to-end deep networks that map raw audio straight to stimulation, closed-loop implants that record neural responses and self-adapt, individualised coding driven by each user's neural health, and optical/optogenetic stimulation aimed at escaping electric current spread entirely.
Sections
Being declared a cochlear implant candidate is not the same as being ready for theatre. Between the moment a team agrees a person could benefit and the moment the array slides into the cochlea lies a structured stretch of work that determines whether the operation is safe, lawful, and worthwhile. This module frames preparation as three jobs: completing the work-up, counselling the patient and family, and setting realistic expectations, and shows how each protects both the surgical outcome and the validity of consent.
Sections
Candidacy answers whether to implant; the medical and anaesthetic work-up answers whether we can do so safely today. Every candidate needs documented fitness to tolerate elective surgery under general anaesthesia, with comorbidities flagged and managed before theatre. This module walks the systems review that matters for a cochlear implant: cardiac (including the QT trap of Jervell and Lange-Nielsen), airway, bleeding and diabetes, plus the CI-specific checks that distinguish this operation from any other ear surgery.
Sections
Recipients of cochlear implants carry an elevated risk of pneumococcal meningitis; this module covers risk, vaccination, and warning signs.
Sections
Cochlear implantation is never a single clinician's decision. Before the patient reaches theatre, a multidisciplinary team converges at a case conference to confirm that the audiological, medical, surgical, psychological and family-readiness criteria are all satisfied, and to lock down the final plan: which ear, which device, and what must be documented. This module walks through who sits at that table, what each contributes, and the pre-operative checklist that must be green before a knife is lifted.
Sections
Counselling is where the technical decision to implant becomes a human one. Good pre-operative counselling does more than disclose risks: it surfaces what the patient or family actually hopes for, tests those hopes against what the evidence promises, and builds the long-term partnership that rehabilitation demands. This module covers the principles of shared and informed decision-making, the tools that support it, and how the conversation differs between an adult choosing for themselves and a parent choosing for a deaf child.
Sections
True informed consent for cochlear implantation means more than a signature. It requires the candidate to understand the specific surgical and device-related risks with their real frequencies, the realistic ceiling of benefit, and the genuine alternatives that exist. This module assembles the numbers a counsellor needs at the bedside, from the rare facial palsy to the irreversible loss of residual hearing, so the choice to proceed is genuinely the patient's own.
Sections
A cochlear implant is fitted to one person but lived with by a whole household. Long before activation, the team must help families understand that the device is the start of a years-long rehabilitation journey, decide together how the child or adult will communicate, and ready the home, school and support network for that work. This module covers the caregiver commitment, communication-mode decisions, and the environment a new ear comes home to.
Sections
An implant is the most effective treatment in medicine for restoring access to sound to a deafened ear, yet it is not a replacement for normal hearing. This module sets the honest baseline: what most recipients gain, what the device cannot deliver, and why the outcome depends as much on the listener's effort, brain and family as on the electrode. Getting expectations right before surgery is itself a predictor of how satisfied the patient will be afterwards.
Sections
No two cochlear implant recipients hear alike, and the spread is not random. Decades of outcome research have isolated a small set of recurring predictors — duration of deafness, age and timing of implantation, pre- versus post-lingual onset, residual hearing, aetiology and nerve survival — that together explain only part of the variance. Knowing what these models can and cannot forecast is the evidence base for honest, individualised counselling.
Sections
Group-specific expectation-setting intro.
Sections
Before any electrode is inserted, the gap between what a candidate hopes for and what the device can deliver is itself a measurable, modifiable risk factor. This module covers questionnaires that quantify expectations, the evidence that unrealistic hopes erode satisfaction even when speech scores rise, and structured screening of depression and cognition that turns psychological readiness into documented data.
Sections
Education before activation builds the rehabilitation alliance and sets realistic expectations for the gradual auditory-learning journey.
Sections
Every preceding step in this chapter, the medical work-up, the vaccination, the counselling, the consent and the expectation-setting, converges on a single reproducible pathway from decision to theatre. This closing module assembles those threads into one operational checklist, so that nothing load-bearing is left to memory. A good checklist is not bureaucracy; it is the mechanism by which a multidisciplinary team guarantees that the right patient arrives at surgery medically fit, fully immunised, properly consented and realistically prepared.
Sections
Cochlear implant surgery is deceptively short, yet every step serves a strict hierarchy of goals: reach the scala tympani safely, anchor the device, slip the array in atraumatically, and bring the patient out with an intact facial nerve and, increasingly, surviving residual hearing. The modern operation is a brief, low-morbidity, often same-day procedure that sits squarely between candidacy work-up and switch-on. This module frames the surgeon's task before later modules dissect the anatomy and the steps.
Sections
The implant surgeon navigates a few cubic centimetres of bone toward a target the size of a grain of rice, guided entirely by fixed landmarks. From the spine of Henle on the mastoid cortex to the round window membrane deep in the middle ear, each structure points to the next, and the facial nerve threads through the whole route. This module walks the landmarks in the order the drill encounters them.
Sections
Audiology decides whether an ear should be implanted; the surgical and anaesthetic team decides whether the patient can safely tolerate the operation that does it. That assessment is a distinct gate, covering fitness for general anaesthesia, hidden cardiac risk in deaf children, the small-child airway and blood volume, and the anaesthetic rule that no long-acting paralytic may abolish facial nerve monitoring. This module covers the medical clearance that runs in parallel with the hearing work-up.
Sections
The implant has to live under the scalp for decades, so the way the surgeon opens and closes the skin matters as much as anything done inside the cochlea. The story of cochlear-implant incisions is one of steady retreat: from a sweeping C-shaped flap that devascularised its own edges, to a small post-auricular line that heals in two weeks. This module follows that evolution and explains how the receiver-stimulator is seated, recessed and tied down so that it neither extrudes nor shears its leads.
Sections
Every implant system in routine use reaches the cochlea the same way: through a cortical mastoidectomy and a posterior tympanotomy that threads between the facial nerve and the chorda tympani. This is the workhorse approach, but it is also where the procedure's most feared complication lives. This module walks the landmarks, defines the boundaries of the facial recess, weighs the heat and proximity that endanger the facial nerve, and introduces the suprameatal and transcanal routes proposed to bypass that window altogether.
Sections
The transmastoid posterior tympanotomy is the road most surgeons travel to the cochlea, but it is not the only one. A family of mastoid-sparing routes — the suprameatal tunnel, pericanal and endomeatal corridors, and endoscope-assisted variants — reach the round window without the facial recess. This module weighs each against the recess approach: what it gains, what it risks, and why the recess still wins most of the time.
Sections
The last few millimetres of the operation decide where the electrode lives. The goal is the scala tympani, the perilymph channel that runs closest to the spiral ganglion, and there are three ways in: through the round-window membrane, through an extended round window, or through a separate cochleostomy on the promontory. This module locates the round window, contrasts the trauma profiles of each route, and explains why the field has swung back toward going through the window the cochlea already provides.
Sections
When Lehnhardt formalised soft surgery in 1993, he reframed cochlear implantation as an exercise in restraint: the cochlea is a closed fluid system, and almost everything the surgeon does to open it can injure the structures inside. This module gathers the manoeuvres that limit insertion force and intracochlear trauma, from a gently opened round window to the advance-off-stylet manoeuvre that keeps a perimodiolar array off the outer wall. The goal is a complete, deeply seated array that has disturbed as little of the membranous labyrinth as possible.
Sections
Many candidates retain useful low-frequency hearing that a hearing aid alone can no longer translate into intelligible speech. Electric-acoustic stimulation (EAS) keeps that acoustic hearing in the implanted ear and adds electric high-frequency information from the array, but only if the surgery spares the apex. This module covers the round-window soft insertion, short and flexible arrays, perioperative steroids, and the slow insertion that together push reported preservation rates toward 80 percent, alongside the real risks of delayed loss and the depth-versus-preservation trade-off.
Sections
Once the array is in the cochlea, the internal package still has to be anchored on the skull so it neither migrates nor wears through the overlying flap. Surgeons trade off between the traditional drilled bony well with tie-down sutures and a well-less subperiosteal tight pocket, and they must respect a thin paediatric skull, the dura beneath it, and decades of skull growth. This module covers seating, fixation, the lead's bony channel, magnet considerations, and how minimal-access technique has reshaped these choices.
Sections
When inflammation has turned the fluid spaces of the cochlea to bone, the surgeon meets a closed door rather than an open lumen. Labyrinthitis ossificans, most commonly after bacterial meningitis, fills the scala tympani from the round window inward, and the operative plan must scale from a routine insertion to a radical drill-out. This module maps the spectrum of obstruction, the imaging clues that forewarn it, and why the clock starts ticking the moment meningitis is diagnosed.
Sections
A malformed inner ear breaks the surgeon's mental map: landmarks are missing, the facial nerve may cross the cochleostomy, and opening the cochlea can release a torrent of cerebrospinal fluid. From the empty common cavity to the subtly partitioned Mondini, each anomaly changes electrode choice, insertion technique, and the risk of stimulating the wrong nerve. This module turns the embryology of arrest into a practical operative checklist.
Sections
Once the array slides home, the surgeon needs answers before the patient wakes: is the facial nerve safe, did the device survive insertion, and is every contact inside the cochlea pointing the right way. A short battery of objective measures, run on the table, converts a blind insertion into a verified one. This module explains what each test proves, what it cannot, and the order in which to trust them.
Sections
A cochlear implant is meant to last a lifetime, but a small fraction of devices must one day be removed and replaced. Revision surgery is driven by hard failures the engineers can document, by soft failures the patient feels but the telemetry cannot prove, and by problems of the surrounding tissue rather than the electronics. The reassuring message of this module is that the deafened cochlea forgives a second visit: the fibrous tract left by the first array usually guides the new one back to depth, and most recipients hear as well or better afterwards.
Sections
For half a century the surgeon's hand has drilled the mastoid and threaded the array, limited by tremor, fatigue, and the irreducible speed at which a human can move. A new generation of image-guided and robotic tools reframes the operation as a planned trajectory and a controlled motion: a keyhole tunnel drilled straight to the round window, and an electrode advanced more slowly and smoothly than any wrist allows. These systems are moving from cadaver bench to early clinical use, and their promise is a gentler cochlea and better preserved residual hearing.
Sections
The implant is in, the wound is closed, and the most important part of the journey to hearing has barely begun. The weeks between surgery and switch-on are not idle waiting; they are a deliberate pause to let the flap heal and swelling settle so the device sits well against a stable scalp. This module follows the recipient from the layered closure and head bandage, through the complications a team watches for, to the handover that turns a surgical patient into a programming patient.
Sections
The cochlea is sealed and the patient asleep. Whatever the surgeon cannot see or ask must instead be measured on the table.
Sections
The drill carving the facial recess runs millimetres from the nerve that moves the face. Continuous EMG turns that nerve into an audible alarm.
Sections
Before the wound closes, the implant is interrogated through its own electrodes: every contact electrically sound, every circuit intact, baselines handed to programming.
Sections
Within seconds of seating the array, the implant can stimulate one electrode and use its neighbours to record the auditory nerve's own answer. The electrically-evoked compound action potential is the surgeon's first proof that the nerve is alive, listening, and reachable across the array.
Sections
The ECAP proves the nerve fires. Two further on-table measures climb higher up the pathway: the stapedius reflex tells us about loud-level tolerance through a brainstem arc, and the eABR confirms the signal actually reaches the brainstem at all — together they verify the route, not just the doorway.
Sections
A tip fold-over or scalar translocation that goes unseen costs the patient a second operation. Caught before the wound is closed, it costs only a few minutes — the array is simply withdrawn and reinserted. This module is about the tools that catch it on the table: the X-ray, the cone-beam CT, and the implant's own field telemetry.
Sections
The array is in, but the operation is not yet over. Before the wound is closed the surgeon must answer one question with as much certainty as the table allows: is this a full, atraumatic, scala-tympani placement? No single test answers it; a small toolkit, read together, does.
Sections
For decades the working assumption was that implantation destroyed whatever residual hearing remained, so it scarcely mattered. That assumption is gone. Preserving residual—especially low-frequency—acoustic hearing is now a goal in every case, because it pays off whether the patient ends up an electric-acoustic listener, a full-electric one, or a future candidate for biological repair.
Sections
Why does an ear sometimes lose its remaining hearing after a technically 'successful' implantation? Because trauma comes in more than one form: the array can wound the cochlea on the way in, and the cochlea can keep injuring itself for weeks afterward. Understanding the mechanisms is what makes soft surgery, electrode design and otoprotective drugs rational rather than ritual.
Sections
Long before drug-eluting arrays or robots, surgeons learned that how the cochlea is opened and entered decides how much hearing survives. Soft surgery is a bundle of small, deliberate manoeuvres - each one mapped to a specific way the inner ear can be harmed - that together turn implantation from a destructive act into a structure-preserving one.
Sections
An array is a foreign body threaded into a 0.3 mm fluid space wound around a delicate membrane. Its shape, stiffness and length decide whether it glides along the outer wall or tears into the hearing organ. Atraumatic design is the second pillar of preservation - and it forces an honest trade-off between protecting hearing and covering the whole cochlea.
Sections
Soft technique and a gentle array reduce the mechanical insult; drugs aim at what follows - the inflammatory, apoptotic and fibrotic cascade the cochlea mounts against trauma and a permanent foreign body. Glucocorticoids lead the field, with anti-apoptotic and anti-oxidant agents and drug-eluting arrays converging on the same goal.
Sections
By recording the cochlea's own electrical response through the advancing electrode, the surgeon can in effect hear the cochlea as the array slides in. A steady, healthy signal says the inner ear is tolerating the insertion; an abrupt drop is a warning to pause, withdraw a little or change course before trauma becomes permanent.
Sections
If we cannot agree on what hearing preservation means, we cannot compare one electrode, surgeon or study with another. Standardised definitions - above all the HEARRING consensus - turn a vague claim of saved hearing into a number that travels, and separate hearing that is merely measurable from hearing that is actually useful.
Sections
Preserved low-frequency hearing is not a vanity metric: combined with the implant it delivers better speech-in-noise, richer music and more natural sound through electric-acoustic stimulation. The same surgery is becoming gentler still - robotic slow insertion, real-time ECochG feedback, closed-loop control and drug-eluting arrays are converging on a future where routine hearing preservation is the expectation, not the exception.
Sections
Surgery places the electrode; programming gives it a voice. The fitting audiologist's task is to translate the everyday acoustic world, which spans roughly 100 dB from a whisper to a shout, into the recipient's narrow electrical dynamic range so that soft is audible, loud is comfortable, and speech is intelligible. This is not a one-day event but a relationship that begins at switch-on and continues for the life of the device.
Sections
Inside every sound processor lives a MAP: the personalised set of parameters that tells each electrode how little current to deliver for a sound the user can just hear and how much for a sound that is loud but comfortable. The gap between those two points is the electrical dynamic range, and it is startlingly narrow. Understanding the MAP means understanding thresholds, comfort levels, charge, and the channels they are written onto.
Sections
Weeks of silence end the moment the processor goes live. For most recipients that day arrives two to four weeks after surgery, and the sound that returns is rarely the sound they remember: voices may be robotic, beeping, or chipmunk-like. The first switch-on is therefore as much a counselling appointment as a technical one, where the audiologist sets a deliberately conservative first map and prepares the recipient for a brain that must relearn how to listen.
Sections
The threshold (T) level is the quietest electrical stimulation a recipient can just detect, and it anchors the bottom of the electrical dynamic range so that soft sounds near 25 dB SPL stay audible without being annoyingly present. Each manufacturer defines T differently, and modern high-rate strategies have made the precise behavioural measurement of T less critical than it once was. This module covers ascending/descending measurement of the just-audible percept, why some clinicians set T low or as a fraction of the upper level, the sweep to confirm audibility, and how methods differ between adults and children.
Sections
The upper-stimulation level (C in Nucleus, M in Advanced Bionics, MCL in MED-EL) sets the top of the electrical dynamic range and is arguably the single most important programming parameter for sound quality and speech recognition. Setting it well means finding loud but comfortable on every channel and then balancing loudness so the array delivers an even percept. This module covers loudness-scaling charts, balancing by sweeping electrode pairs, global and profile adjustments, and the real risks of levels set too high or too low.
Sections
Frequency allocation is the filter-bank table that decides which input frequencies are routed to which electrode, and therefore which cochlear place each sound stimulates. Because most arrays sit shallower than the cochlear region that naturally codes their assigned frequencies, recipients begin life with a place-frequency mismatch they must adapt to, and the audiologist must weigh matching cochlear place against keeping a wide speech bandwidth. This module covers the default filter maps, the mismatch from shallow insertion, frequency importance, and when (and whether) to reassign frequencies.
Sections
By the time a recipient reaches the programming booth, the engineering debate over coding strategies has narrowed to a handful of clinic-level decisions: which strategy family to run, how fast to pulse each channel, and how many channels to fire per analysis cycle. These choices are not independent, rate, maxima and pulse width are bound together by the device's fixed total stimulation budget, and they trade off against loudness, sound quality and battery life. The defaults shipped by each manufacturer are sensible starting points, but the evidence is clear that the individual optimum varies, and the clinician's job is to know when to move off default.
Sections
Before any coding strategy fires a single channel, the sound processor's front end has already made decisive choices: how much of the acoustic world to let through, how loud to make it, and how to favour the talker over the room. Input dynamic range, microphone sensitivity and automatic gain control together squeeze a 100-plus-decibel acoustic landscape into a narrow electrical window of perhaps 40 to 60 dB. Layered on top are directional microphones, noise-reduction algorithms and scene classifiers that decide, moment to moment, what counts as signal.
Sections
Programming an infant or toddler inverts the usual fitting logic: the clinician cannot simply ask whether a sound is comfortable, because the child cannot reliably say. Instead the audiologist reads behaviour, leans on objective measures, and accepts that the first map is a starting point to be shaped over weeks rather than perfected in one visit. The guiding principle is conservatism, and because auditory brain development runs against the clock, that patience must be matched by urgency.
Sections
Objective measures let the audiologist interrogate the implant when the patient cannot speak for it. Impedance telemetry confirms every contact is electrically sound, while the evoked compound action potential, the stapedial reflex and the electrical brainstem response sketch a physiological profile the MAP can be built upon. But the link between what the nerve reveals and what the listener needs is loose, so these tools start the map rather than finish it.
Sections
Even a technically perfect implant can deliver a disappointing or unpleasant signal, and many complaints trace back to one or two electrodes rather than the whole device. Facial twitching, dead channels, scrambled pitch, dizziness and a tinny or sharp percept each have a recognisable signature and a systematic fix. The audiologist's tools are impedance telemetry, electrode sweeping, and targeted changes to C level, pulse width, coupling and channel allocation.
Sections
Some recipients fall well short of expectation despite a device that powers on and passes telemetry. The work-up moves from the simplest, most reversible causes outward: external hardware, then internal integrity and impedances, then electrode position on imaging, then the map itself, and finally the patient's biology, cognition and engagement. A disciplined stepwise algorithm prevents the two classic errors, blaming the patient for a device fault and reprogramming endlessly around a problem that imaging would have revealed.
Sections
Most implant users do not listen with one device in isolation. A growing majority pair the implant with a hearing aid on the other ear (bimodal), wear a second implant (bilateral), or use an implant to restore an utterly deaf ear beside a near-normal one (single-sided deafness). In every case the fitter's job extends beyond a single map to the harder problem of making two unlike devices behave as one auditory system.
Sections
Not every cochlea is a clean tonotopic spiral waiting for a full electrode array. Some ears keep useful low-frequency hearing the surgeon worked to preserve; others are ossified, malformed or accept only a partial insertion; still others answer stimulation with a twitch of the face rather than a sound. Each demands a map built around what the ear actually offers rather than the textbook default.
Sections
Activation is the start of programming, not its conclusion. Over the first weeks the cochlea, the nerve and the listener all change, so the map is chased toward stability rather than set once. Datalogging now reports how the device is actually lived with, remote sessions reach patients who cannot travel, and sound-field and speech verification turn a map that looks reasonable into a recipient who can hear soft speech.
Sections
Ask whether a cochlear implant worked and you invite a single number in reply. But hearing is not one skill, and a recipient who scores 60% on a word list may still be the person who can finally use the telephone, follow a grandchild across a noisy room, or stop watching lips. Outcome is plural, layered, and stubbornly individual, and the average score conceals as much as it reveals.
Sections
If outcome is plural, measuring it demands a battery rather than a single test. Modern practice pairs open-set monosyllables with open-set sentences, tests in quiet and increasingly in noise, and reaches for closed-set tasks when a listener is too young or too new to manage open-set material. The art lies in choosing materials hard enough to avoid the ceiling yet fair enough to reflect real listening.
Sections
Switch-on is not the finish line but the start of a curve. For the postlingually deafened adult, speech understanding climbs steeply in the first weeks and months, then bends toward a plateau by somewhere between three months and a year, after which most of the gains are slow and incremental. Understanding the shape of this curve is what lets clinicians counsel honestly and judge when a result is settled.
Sections
Give a hundred postlingually deafened adults the same implant, the same processor and the same strategy, and at one year their open-set word scores will scatter across almost the entire scale, from near zero to ceiling. This irreducible spread, and our limited ability to predict where any one patient will land, is the central clinical and counselling challenge of adult cochlear implantation.
Sections
If a single number had to be chosen to forecast how a postlingually deafened adult will do with an implant, it would be the length of time the ear was severely or profoundly deaf before surgery. Duration of auditory deprivation, the age at which deafness began, and to a lesser and largely derivative degree the patient's age at implantation, form the demographic core of adult outcome prediction.
Sections
An implant can only do as much as the ear and nerve it stimulates allow. Residual hearing and aetiology, the survival of spiral ganglion cells and the cochlear nerve, and the final resting position of the electrode array all shape the interface between current and neuron. Yet the peripheral substrate is frustratingly hard to measure in life, and even direct histology predicts outcome only loosely.
Sections
An implant delivers a sparse, degraded signal; what the listener makes of it depends as much on the brain behind the ear as on the electrode inside it. Working memory, processing speed and the capacity to fill gaps with prediction help explain why two recipients with identical audiograms can sit a world apart on a word test. This module treats cognition as an outcome modifier in its own right, and looks at why older recipients, despite measurable central decline, still benefit.
Sections
For a deaf child, the implant is judged not by a word score but by whether spoken language, reading and a mainstream classroom become realistic. The CDaCI study followed implanted children prospectively and showed that the device reliably bends the language-growth trajectory upward, that age at implantation matters, and that the earliest-implanted children can track close to hearing peers. A residual gap often persists, most visibly in reading and writing, but the population-level shift since the pre-implant era is large.
Sections
Beyond comprehension lies expression: can the child be understood, and can she build vocabulary and grammar at something like a typical pace? Early-implanted children can reach high speech intelligibility, often most of their words understood by an unfamiliar listener, and many follow vocabulary and grammar trajectories that approach those of hearing peers. The same modifiers recur, age at implant, communication emphasis and family involvement, and so does the wide individual variability that defines paediatric outcomes.
Sections
A quiet-booth word score is the easy half of the story. The everyday world is noisy and spatially complex, and it is here that even the best implant users still fall short of normal hearing. This module measures that gap: how speech-reception thresholds are tracked in noise, how separating talker from masker in space helps a single implant only modestly, and why locating a sound remains the hardest thing for one ear to do.
Sections
The implant was engineered for speech, and it shows. Rhythm survives the journey through the device almost intact, but the spectral fine structure that carries melody, instrument colour and the pitch of a voice is heavily degraded. This module measures what reaches the listener: poor melody and timbre, surprisingly preserved rhythm, and a voice from which gender and emotion are only partly recoverable.
Sections
Almost everything that limits a single implant, poor noise tolerance, weak spatial release, absent localisation, is a consequence of listening with one ear. Restoring a second input, whether a second implant, a contralateral hearing aid, or an implant for a single deaf ear, recovers part of what binaural hearing provides. This module measures those gains and names the mechanisms behind them.
Sections
A booth score answers one question: how many words did the recipient repeat back today, in this room, from this loudspeaker. It says little about whether they can follow a grandchild across a noisy kitchen, locate a car at a crossing, or enjoy music again. Patient-reported outcome measures close that gap by asking the only person who lives with the implant all day. This module covers the communication- and hearing-specific self-report instruments used after cochlear implantation, and where self-report is powerful and where it misleads. Health-utility and cost questions belong to the next chapter; here the currency is the recipient's own account of hearing.
Sections
Most outcome data come from the prototypical recipient: a postlingually deafened adult with a normal cochlea and cochlear nerve, implanted after a manageable interval of deafness. Many recipients are not that person. The elderly, the very-long-duration and prelingually deaf adult, the patient with auditory neuropathy spectrum disorder, and the child or adult with cochleovestibular malformation or additional disabilities all sit further from the mean, and their outcomes are wider, slower and sometimes harder to read against a sentence score. The recurring message is that the distribution shifts and widens, yet the benefit is usually still real; the task is to define benefit appropriately for each group.
Sections
Patients and clinicians want a number before surgery: how well will I hear? Three decades of large datasets have produced prediction models built from the obvious variables, duration of deafness, age, etiology, residual hearing, and these variables are real and statistically robust. Yet they explain only a small fraction of the variance between recipients, which is why a preoperative model can describe a population but cannot promise an individual a score. This module covers the major prediction efforts, the humbling amount of variance they leave unexplained, how registries let a clinic benchmark its own results, and when a result below benchmark should trigger the poor-performer work-up.
Sections
A cochlear implant restores access to sound, not the skill of understanding it. The device delivers a sparse, unfamiliar electrical pattern to the auditory nerve, and the brain must learn to map that pattern onto meaning. Whether the recipient is a child building a language code for the first time or an adult relearning a familiar one, rehabilitation is the bridge from raw audibility to genuine communication, and engagement with it is one of the strongest determinants of outcome.
Sections
No single professional rehabilitates an implant recipient. Listening is rebuilt by a multidisciplinary team in which the audiologist, the speech-language pathologist or listening-and-spoken-language specialist, the teacher of the deaf, and the psychologist each contribute, while the family acts as the primary agent of change. This module follows the pathway from activation through intensive early therapy to long-term support, and the goal-setting that ties it together.
Sections
Rehabilitation works because the brain is plastic, but that plasticity is not unlimited or timeless. Central auditory pathways pass through a sensitive period during which they must receive organised input to mature normally, and prolonged deafness lets other senses colonise auditory territory. Understanding this biology explains why early implantation, consistent stimulation, and sustained training matter so much, and why adult plasticity, though it persists, works more slowly.
Sections
An implant restores access to sound, but the brain still has to learn to make sense of it. Auditory training is the deliberate, structured practice that turns a new electrical signal into meaningful listening, organised around a hierarchy of skills, a choice between bottom-up and top-down methods, and the disciplined grading of difficulty.
Sections
Auditory-Verbal Therapy is a parent-centred approach to helping a deaf child learn to listen and talk, with hearing as the primary channel. It rests on early diagnosis and fitting, a practitioner who coaches the family rather than drilling the child, and listening woven into the fabric of everyday life.
Sections
The most powerful intervention for a young implanted child is not delivered to the child at all; it is delivered through the family. Family-centred early intervention coaches caregivers to build a language-rich home, because responsive, engaged parenting is the single most modifiable predictor of a child's language outcome.
Sections
The implant restores access to sound, but spoken language is built, not switched on. This module follows the therapy that turns a newly hearing brain into a talking child: listening before babble, babble before words, words before grammar, paced not to chronological age but to the child's listening age, and driven by the quantity and quality of language the family pours in.
Sections
A child cannot reliably produce a sound they cannot hear. By restoring access to the speaker's own voice, the cochlear implant reopens the auditory feedback loop that governs intelligible speech, this module covers the therapy that builds clear speech on top of it: working on vowels and consonants, on the melody and rhythm that carry naturalness, on the characteristic error patterns of implanted children, and on the self-monitoring that makes gains permanent.
Sections
For a post-lingually deafened adult, the implant does not teach a new skill, it reconnects an old one to a changed signal. The brain that once heard normally must now relearn to map an electric, spectrally degraded input back onto speech it already knows. This module covers the relearning: structured and home-based auditory training, graded listening and telephone work, counselling and realistic expectations, the role of communication partners, and the uncomfortable reality that adults are often offered far less formal rehabilitation than children.
Sections
An implant restores access to sound, but it does not restore a conversation. Communication-strategy training teaches the recipient and the people they talk to a set of pragmatic tactics, anticipatory planning, repair moves, speechreading, and environmental control, that turn an imperfect electric signal into successful everyday exchanges.
Sections
The quiet clinic is the easiest listening situation a recipient will ever face. Real-world rehabilitation deliberately reintroduces noise, distance, the telephone and the chaos of daily life, and recruits remote-microphone and streaming technology, so that gains made in structured tasks carry over to the places where people actually need to listen.
Sections
Music is the hardest signal an implant has to carry: it leans on the fine pitch and timbre cues the electric signal represents worst. Yet music perception is trainable. Structured music rehabilitation works rhythm-first, then timbre and melody, leans on any residual acoustic hearing, and sets honest goals, renewed enjoyment and engagement rather than normal music perception.
Sections
When the therapist cannot be in the room, the listening work need not stop. Telepractice coaches families and trains adults over a video link, while app- and computer-based auditory training turns daily practice into something a child will choose to do. Together they stretch a scarce specialist workforce across rural and low-resource settings, and a small but consistent evidence base suggests the gains can match the clinic.
Sections
An implant gives a child access to sound, but a classroom can take much of it away again. Noise, distance and reverberation erode the signal a young listener needs, so educational support pairs better acoustics and remote-microphone technology with skilled people: the teacher of the deaf, the itinerant support service, and a written plan that follows the child. The goal is not merely placement in a mainstream room but genuine access to the curriculum within it.
Sections
Booth speech scores tell you how a recipient performs on a test; functional listening tools tell you how they live. The daily Ling six-sound check confirms the device is delivering sound across the speech range, while parent and teacher questionnaires track real-world listening and spoken-language milestones over months and years. Read together against expected trajectories, these tools steer therapy, flag a stall early, and decide when to loop back to the programming and outcomes workup.
Sections
An audiogram tells you a sound was detected; it does not tell you whether a life got better.
Sections
Quality of life sounds too soft to measure, yet health economics turns it into a single number between 0 and 1. This module explains what health-related quality of life means, how a health state is converted into a utility where 0 is death and 1 is perfect health, and how that number becomes the raw material a QALY needs. Along the way we meet the three classic ways patients are asked to value a health state, and the difference between generic and disease-specific measurement.
Sections
Generic preference-based instruments turn a described health state into a single utility, anchored at 0 (death) and 1.0 (perfect health), so a cochlear implant can be compared against any other treatment. This module unpacks HUI3, EQ-5D and SF-6D, how each maps a state to a utility, why HUI3 is the CI workhorse because it contains a hearing attribute, and why generic measures are insensitive to hearing.
Sections
Generic utility measures answer the economist's question but miss what an implant actually changes for the listener. Disease-specific instruments are built to capture sound perception, listening effort, and the social handicap of deafness — the very domains generic tools blur. This module surveys the adult and pediatric instrument families, what each measures, and how to match the questionnaire to the question.
Sections
Cochlear implantation in deaf adults reliably lifts measured health-related quality of life. This module quantifies that gain, names the instruments that capture it, identifies who benefits most, and traces the evidence from single-sided deafness through the elderly to the cognition-loneliness-depression axis.
Sections
Measuring quality of life in a deaf child is harder than in an adult: the child often cannot self-report, the benefit unfolds over years, and the implant changes the whole household, not just one ear. This module follows the conceptual chain from auditory function to family wellbeing, weighs parent-proxy against child self-report, and confronts the methodological traps of asking what a good life means for a deaf child.
Sections
Deciding whether an implant is worth it is an economic question, and economists have a small, precise vocabulary for it. This module builds that toolkit: the QALY as utility times time, the ICER as cost per QALY, and the discount rate, perspective and threshold that turn a cost-per-QALY into a funding decision. By the end you should be able to read a cost-utility paper and judge whether its bottom line is robust.
Sections
- Utility and the QALY: putting a number on a year of life
- Eliciting utility: direct methods and off-the-shelf instruments
- The ICER: the price of an extra QALY
- Discounting and perspective: whose costs, and when
- Thresholds and sensitivity analysis: turning a ratio into a decision
- Clinical case
- Self-assessment
An implant is not a one-off purchase. The cost side runs for the rest of the recipient's life: device, surgery, hospitalisation, programming, rehabilitation, processor upgrades, batteries, maintenance and the occasional revision. This module unpacks that ledger, how a lifetime cost model is built, and why future costs are discounted before being set against QALYs.
Sections
A cochlear implant is expensive, so payers ask whether the hearing it restores justifies the price. Cost-utility analysis converts hearing gain into quality-adjusted life years and divides cost by that gain. Across the landmark adult studies the verdict is consistent: unilateral implantation in postlingually deaf adults sits near the top of the value table, inside the thresholds payers use to fund care.
Sections
Test standfirst sentence one. Test sentence two for the intro paragraph here.
Sections
The first implant is one of the most cost-effective operations in medicine. The second is not, and that gap is the heart of why bilateral implantation, single-sided deafness, and the elderly recipient each force a separate economic argument. This module works through the incremental cost-effectiveness logic that makes the second ear a harder sell than the first, and shows where the threshold either rescues or rejects each of these harder cases.
Sections
A cochlear implant is bought once but pays out over a lifetime, and much of that return lands outside the clinic. This module reframes the implant as a societal investment: the utility lost to profound deafness, the cost per quality-adjusted life year of restoring hearing, and the educational and productivity offsets that turn an apparently expensive device into one of medicine's better bargains.
Sections
Every cost-utility verdict so far carries a hidden assumption: that the country paying can afford the threshold. Shift the willingness-to-pay ceiling from a rich economy to a poor one and the same implant, with the same clinical benefit, can move from clearly worth it to economically unjustifiable. This module follows the cost-effectiveness argument out of the high-income clinic and into the low- and middle-income world, takes India as a worked example, and closes the chapter on the equity question the numbers cannot settle alone.
Sections
Most of what is taught about cochlear implant candidacy is built around two reference patients: the post-lingually deafened adult who lost a working auditory system, and the congenitally deaf infant whose system is implanted before the critical window closes. Real clinics are full of people who fit neither template. This chapter is about those patients, and the principle that runs through all of them: candidacy is not a fixed threshold but a frontier that has steadily moved outward, and the lower the certainty, the more honest the counselling must be.
Sections
For most of cochlear implant history, having one normal ear made you ineligible. Single-sided deafness inverts the classic logic: the problem is not audibility but the absence of two ears working together. Since the U.S. FDA approved implantation for single-sided and asymmetric loss in 2019, the operation has had a clear set of goals unlike any other indication, and a clear limit set by how long the deaf ear has been silent.
Sections
Auditory neuropathy spectrum disorder is the diagnosis that breaks the audiogram. The outer hair cells work, sound enters the cochlea, yet the message to the brain arrives smeared or not at all. Whether a cochlear implant helps depends on a single question that the pure-tone audiogram cannot answer: where exactly along the pathway is the lesion, and is the cochlear nerve still there to be stimulated.
Sections
An implant can only excite a nerve that exists. When the cochlear nerve is small or absent, the question shifts from whether to implant to whether there is enough neural substrate to make an implant worthwhile, and when to look past the cochlea altogether.
Sections
Most malformed ears can hear with an implant, but the spread of outcomes is wider than in a normal cochlea, and it tracks two things above all: whether a cochlear nerve is present and how far down the developmental scale the malformation sits.
Sections
Bacterial meningitis is one of the great preventable causes of acquired deafness, and it sets a clock running: the cochlea begins to fill with bone within weeks. Here the implant decision is a race against ossification, and timing matters more than almost any other variable.
Sections
When the bony labyrinth or the membranous inner ear is itself diseased, the ear can still be implanted and can hear well, but the disease leaves a signature that shapes both the surgery and the complications to expect. Far-advanced otosclerosis, end-stage Meniere's disease, chronic suppurative otitis media and the open mastoid cavity each pose distinct candidacy and counselling problems, and the recurring principle is that the underlying pathology, not the audiogram alone, predicts the difficult cases.
Sections
The trajectory of childhood deafness is set early, and the case for implanting before the first birthday rests on the sensitive period for central auditory development. In 2020 the FDA lowered the approved age for the first device to nine months, formalising a practice many centres had already adopted. The benefit is earlier access to sound during the window of greatest cortical plasticity; the price is the difficulty of proving profound loss in a tiny infant and operating safely on a small skull under general anaesthesia.
Sections
There is no upper age limit for cochlear implantation. Older adults gain real speech understanding and quality-of-life improvement comparable to younger recipients, even if their gains arrive more slowly and may plateau at a somewhat lower level. The gate to candidacy is medical and anaesthetic fitness, not the number on the birth certificate. Layered over this is the growing recognition that hearing loss and cognitive decline are intertwined, and that treating the hearing loss may protect the ageing brain.
Sections
Roughly one in three deaf children carries a second condition, developmental delay, cerebral palsy, autism spectrum disorder, visual impairment or cognitive impairment. An additional disability rarely excludes implantation, but it reshapes the conversation: goals become individualised and sometimes non-verbal, progress is slower and more variable, and success is measured by function and connection rather than by sentence scores.
Sections
When deafness is one feature of a named syndrome, the diagnosis carries information well beyond the audiogram. It can change the urgency of surgery, dictate cardiac and anaesthetic safeguards, predict the surgical anatomy, and reset the family's expectations. This module walks through the syndromes a cochlear implant team meets most often and shows how each one alters timing, planning and care.
Sections
The congenitally deaf teenager or adult who has never heard well presents the hardest counselling problem in candidacy. The sensitive period for spoken-language development has closed, so open-set speech is unlikely. Yet many still gain meaningful access to environmental sound, support for lip-reading and a real lift in quality of life, provided the right candidate is chosen and expectations are set with care.
Sections
Some of the hardest candidacy decisions are not about whether the implant will work, but about how much is at stake if it does not. Operating on a person's only or better-hearing ear, or on a patient whose heart, blood, or immune system narrows the surgical margin, turns selection into a deliberate exercise in shared risk. The evidence is reassuring more often than instinct expects, but it must be earned case by case.
Sections
When there is no usable cochlea and no usable cochlear nerve, the cochlear implant has nothing to stimulate. The auditory brainstem implant steps over the missing parts entirely, placing an electrode array directly on the cochlear nucleus in the floor of the lateral recess. It is a harder operation for a more modest reward, but for the right candidate it is the only road to hearing.
Sections
The largest special population of all is defined not by anatomy or comorbidity but by geography and income. Most of the world's deaf people live where cochlear implants are barely available, and where the audiology, rehabilitation, and lifelong follow-up that make an implant work are scarcer still. For this population the limiting factor is not candidacy but access, and equity is the defining clinical challenge.
Sections
About one in five congenitally deaf ears is built wrong in a way you can see on a scan. Those ears rewrite every rule of implantation.
Sections
The inner ear is a coil built in eight weeks from a patch of skin. Read a malformation and you are reading the week the building stopped.
Sections
Three classifications turned a spectrum of misbuilt cochleae into named categories — and each leaves out the one structure that decides candidacy.
Sections
At the very tip of the Sennaroglu spectrum sit two anomalies where the inner ear barely exists at all. Michel aplasia is the total absence of the labyrinth; the rudimentary otocyst is a millimetre-sized remnant that never matured. Both share a fatal flaw for cochlear implantation: there is nothing to stimulate, and usually no cochlear nerve. Recognising them on imaging is what redirects the child toward an auditory brainstem implant rather than a futile cochleostomy.
Sections
One step less severe than Michel aplasia, these anomalies share a theme of cochlear shortfall. In cochlear aplasia the cochlea is absent while a vestibule survives; in cochlear hypoplasia a small cochlea forms but is reduced in turns, size, or both. The clinical fork is sharp: aplasia gives nothing to implant, while many hypoplastic cochleae can be implanted with short or special arrays - and outcome follows the surviving neural tissue.
Sections
When the otocyst arrests around the fourth to fifth week, the cochlea and vestibule never separate - they fuse into a single ovoid chamber with no internal partition and no modiolus. The neural elements are not gathered in a central core but smeared around the cavity wall, which rewrites the whole surgical problem. The implant must address a wall, not a coil, and it must do so against a high risk of gusher and an unpredictable facial nerve.
Sections
In the incomplete partitions the cochlea has won its outward argument with embryology — it is the right size and roughly the right shape — but lost the inner one. The modiolus and the interscalar septa, the bony scaffolding that should divide the spiral into turns and carry the nerve up its core, are partly or wholly missing. Three patterns recur, and telling them apart on the scan tells you the gusher risk, the electrode you should reach for, and what to promise the family.
Sections
The vestibular aqueduct is a slender bony channel carrying the endolymphatic duct from the vestibule toward the posterior fossa. When it is too wide it becomes the most common radiological inner-ear anomaly in children with sensorineural loss — and a clinical story of hearing that slips down a staircase, sometimes after a knock to the head. It rarely changes whether you implant, but it changes how you measure, what you tell the family, and what you expect when you open the cochlea.
Sections
An implant is a transducer; it needs a wire on the far side. That wire is the cochlear nerve, and whether it exists decides cochlear implant versus auditory brainstem implant far more than the shape of the cochlea does. A beautifully formed cochlea with no nerve cannot hear; a grossly malformed cochlea with a healthy nerve often hears well. This module is about how to find the nerve before you commit — on CT through the bony canal it travels in, and on MRI by looking at the nerve itself.
Sections
CT and MRI are not rivals but partners. CT draws the bone - the cochlear turns, the modiolus, the width of the canal that carries the nerve. MRI fills the labyrinth with bright fluid and, on the right oblique slice, shows whether a cochlear nerve is actually there. Neither alone defines candidacy in a malformed ear; together they do.
Sections
A malformed cochlea is the visible end of a developmental program that went off course, and increasingly we can name the gene. SLC26A4 makes the dilated aqueduct, POU3F4 the gushing IP-III, CHD7 the canal-less CHARGE ear. Knowing the genotype predicts the associated anomalies, the gusher, the recurrence risk - and, by telling membranous from neural disease, often the implant outcome.
Sections
The malformed ear punishes assumptions. A defective modiolus turns a cochleostomy into a fountain of CSF; an aberrant facial nerve crosses the very window the surgeon wants to open; a featureless common cavity offers no scala to follow and a treacherously close internal auditory canal. The anomaly type, read from imaging, largely predicts which of these the surgeon will meet.
Sections
A malformed cochlea changes both what you put in and what you promise afterwards. Matching the electrode to the anomaly minimises misplacement, while the anomaly and the cochlear nerve together set the outcome range you must counsel honestly.
Sections
Anatomy classifications name the deformity but stop short of telling you what to do. This chapter's centrepiece is a prognosis-oriented algorithm - the author's own research - that drives from hearing status and imaging through eight questions to a treatment, a surgical-difficulty forecast and a prognosis.
Sections
The whole chapter resolves into one pathway: three branch points sort every malformed ear into one of four destinations. Around that skeleton sit the team, the parent conversation and the honest prognosis.
Sections
Nature gave us two ears for a reason. A single implant restores hearing, but listening with one ear leaves spatial awareness, effortless comprehension, and noise tolerance on the table.
Sections
The brain locates sound by comparing two ears: tiny timing differences for low frequencies, loudness differences for high. This module explains the duplex theory and why implants relay one cue far better than the other.
Sections
Hearing in noise with two ears comes from three measurable advantages. This module defines and quantifies head shadow, summation and squelch, and explains which ones bilateral implant users reliably obtain.
Sections
A single implant gives a person sound but not a direction. Add a second ear and the listener can suddenly point to a voice, a car, or a child calling from another room. Localization is the cleanest, most reproducible benefit of bilateral implantation — here is how it works and why it matters.
Sections
Ask cochlear implant users what they want most and the answer is rarely 'more localization' — it is to follow a conversation when the room is noisy. A second ear helps, but mostly through a simple geometric trick rather than true binaural fusion. Understanding how it helps explains both its real value and its limits.
Sections
Laboratory effect sizes for a second implant can look modest — a few degrees of localization, a few decibels of SNR. Yet patients who have two ears rarely want to go back to one. This module bridges that gap: the everyday currency of bilateral hearing is reduced effort, spatial awareness, and confidence, captured by self-report and patient preference more than by any single booth score.
Sections
Bilateral hearing can be restored in a single operation or built up across two. The choice shapes anaesthetic exposure, theatre time, cost, and—most consequentially in children—the developmental window in which the brain receives symmetric input.
Sections
When the two ears are implanted in turn, the time between them is not neutral. In a developing brain a widening gap leaves the second ear behind—slower to mature, poorer in outcome, and increasingly out-competed by the first.
Sections
A child does not just need to hear—she needs to locate a voice in a noisy classroom, follow conversation across a dinner table, and absorb the language drifting around her. Two implanted ears, given early, build the binaural brain that makes this possible.
Sections
A single implant restores hearing; a second restores the geometry of two ears. For adults the gains are real but smaller than the first implant, and the economics are harder. This module weighs the trial evidence, identifies who benefits most, and frames an honest counselling conversation about the second ear.
Sections
Not every second ear needs a second implant. When the non-implanted ear keeps useful low-frequency hearing, a hearing aid on that side and a cochlear implant on the other combine acoustic fine structure with electric detail. This is bimodal hearing, and for many adults it is the most cost-effective way to hear with two ears.
Sections
Two ears hearing by two different mechanisms will not automatically fuse into one percept. Bimodal fitting is the clinical craft of balancing an electric ear against an acoustic ear so that loudness, timing and frequency content line up well enough for the brain to combine them. Done badly, the worse ear can drag the better one down.
Sections
A second implant buys real benefit, but it does not rebuild a binaural system. Two independent processors, envelope-only coding and unlinked gain control quietly demolish the microsecond timing cues the brainstem needs. Here is the engineering reason fine interaural timing is the casualty, why level-based localization survives, and what synchronized processors are trying to put back.
Sections
One implant, two implants, or one implant plus a hearing aid — the right answer depends on what is left in the other ear, how old the patient is, what they want to hear, and who is paying. This module turns those variables into a practical algorithm that ties the chapter together.
Sections
The first implant is one of the most cost-effective interventions in medicine; the second ear costs more per quality-adjusted life-year for a smaller marginal gain — yet often still clears accepted thresholds, especially in children. This module weighs the economics of the second ear, the access gap that still denies many a first, and the engineering future that could finally make two implants behave like two ears.
Sections
The cochlea is not a private room — it opens onto the vestibule and its five balance organs through one continuous perilymphatic space. Inserting an electrode is therefore never vestibularly silent: it carries a real, test-dependent risk of injuring the labyrinth next door. This opening module frames the central justification for vestibular assessment around implantation.
Sections
Unlike the cochlea's single sensory organ, each labyrinth carries five. Three semicircular canals sense angular acceleration and drive the vestibulo-ocular reflex; two otolith organs sense linear motion and gravity and drive postural reflexes. Understanding their tonic firing, push-pull pairing, and reflex outputs explains both why implantation injures them and why a single test cannot declare them dead.
Sections
The most striking lesson of temporal-bone and pressure studies is that the implant rarely tears the vestibule open. Instead it injures the labyrinth through hydraulic pressure transients during insertion, perilymph and endolymph disturbance with hydrops, and a delayed fibrotic reaction — with the saccule most exposed. Reframing injury as fluid mechanics turns prevention into a soft-surgery problem.
Sections
Many of the insults that cause profound deafness also injure the labyrinth, so a large share of candidates arrive already vestibularly impaired. The etiology of the hearing loss predicts the pattern of vestibular risk, and roughly half of candidates have some bilateral weakness before any surgery — the clinical baseline against which any surgical loss must be judged.
Sections
History is the first vestibular test. Separating true vertigo from non-vestibular dizziness, then reading the timing and triggers of episodes, localizes the cause before any machine is switched on. A focused bedside screen — Frenzel lenses, head thrust, tandem Romberg, dynamic visual acuity — plus a review of the planning scan can flag asymmetry in under five minutes.
Sections
No single vestibular test equals a dead labyrinth. Like the cochlea, the vestibular periphery is frequency-tuned, and each canal test probes a different stimulus frequency — caloric at the bottom, head impulse at the top. Combined, they map the canals like an audiogram maps the cochlea, so hypofunction in one band is not areflexia.
Sections
The canal tests miss the organ most often injured by implantation. Vestibular-evoked myogenic potentials probe the otoliths — cervical VEMP the saccule, ocular VEMP the utricle — and posturography and subjective visual vertical capture the functional whole. Because cVEMP is the most sensitive marker of CI-induced injury, the otolith half of the battery is not optional.
Sections
After implantation the clinician must separate true labyrinthine pathology — with objective nystagmus or measurable deficit — from benign nonspecific dizziness related to anesthesia and general factors. Onset timing tells a story: immediate dizziness is surgical, a delayed cluster of vertigo, fullness and tinnitus is hydrops-like, and positional spinning is BPPV. Treatment is matched to cause and severity.
Sections
Vestibular testing earns its place largely at this decision. When function is asymmetric, implant the worse-balancing ear so the patient keeps the better labyrinth. Bilateral implantation multiplies the benefit but also the hazard of iatrogenic bilateral loss — the decision pivots on baseline status, etiology and a careful weighing of the only-balancing-ear risk.
Sections
Because both residual hearing and vestibular function fall to the same hydraulic and fibrotic insults, the same soft-surgery lever protects both. Round-window entry, slow insertion, stable slim arrays and peri-operative steroids each lower the pressure transient and the foreign-body reaction. Structure preservation reframes balance protection as a surgical-technique decision.
Sections
In children, vestibular loss is not mainly about dizziness — children compensate well — but about gross-motor milestones, reading, safety and even device survival. Vestibular impairment is common in deaf children, worsened (especially otolith function) by implantation, and when bilateral and complete it delays sitting, standing and walking. Early identification lets rehabilitation start sooner.
Sections
Older recipients sit at the intersection of presbyvestibulopathy, hearing loss and fall risk, and they are more likely than younger patients to lose vestibular function with surgery. Yet much of their post-op disequilibrium reflects slow re-integration of sensory inputs rather than new labyrinthine signs, and it usually recovers with vestibular rehabilitation. The older recipient is a rehabilitation story as much as a surgical one.
Sections
As bilateral implantation makes iatrogenic bilateral vestibular failure more likely, the same engineering that restored hearing is being turned on balance. A multichannel vestibular prosthesis stimulates the semicircular-canal ampullae to restore three-dimensional motion sensing, and combined cochleovestibular devices are on the horizon. The chapter closes where it began: the labyrinth next door, now a target for restoration rather than only a casualty.
Sections
Cochlear implantation is remarkably safe. A shared taxonomy of major versus minor complications turns that reassurance into something you can audit and improve.
Sections
The receiver sits under a flap of scalp that must heal over hardware and a magnet. When that skin fails, the device underneath is at stake.
Sections
A foreign body in the body is a scaffold for bacteria. Understanding biofilm explains why some implant infections clear with antibiotics and others never will.
Sections
Cochlear implantation is one of the safest operations in otology, but the few things that can go wrong inside the temporal bone are consequential. This module walks the surgeon's path of risk: the facial nerve in the recess, the chorda tympani, the dura, the perilymph gusher of the malformed ear, bleeding, and the misplaced array recognised before the patient ever leaves the table.
Sections
An array that reaches the cochlea is not the same as an array that reaches the right place. This module covers the geometry of failure - the tip that doubles back, the array that crosses the basilar membrane into the wrong scala, the insertion that stops short, and the lead that creeps out over the years - and how each is found and fixed.
Sections
Sometimes the implant simply stops, and sometimes it works on the bench yet fails the patient. This module draws the line between hard and soft failure, explains the integrity test and why a normal result does not exonerate the device, and follows the cumulative-survival reporting and consensus statements that let centres and families weigh the decision to reimplant.
Sections
An electrode array sits a few millimetres from the labyrinthine segment of the facial nerve, separated only by the thin otic-capsule wall. When that wall lets current leak, the recipient gets a twitch instead of a tone. Facial-nerve stimulation is the textbook example of current going where it was never meant to go, and the most instructive complication to troubleshoot.
Sections
Facial twitching is the famous off-target percept, but it is not the only one. Some recipients feel pain, a pulling or throbbing, a needle-like body sensation, or a wave of dizziness when certain electrodes fire. Each is current reaching a structure other than the auditory nerve, and each is troubleshot the same disciplined way: find the culprit electrode, soften or silence it, and protect speech.
Sections
The cochlea and the vestibular labyrinth share a fluid-filled house, so opening one can unsettle the other. Many recipients feel transiently off-balance after surgery; a smaller number develop true vertigo, delayed positional spells, or, rarely, persistent imbalance. Knowing the expected course lets you reassure most patients and work up the few who need it.
Sections
Some recipients never reach the scores their candidacy predicted; others slip backwards after years of stable hearing. Both are 'poor performers,' and both deserve the same discipline: a structured, stepwise differential that interrogates the device, the cochlea, the map, and the brain before anyone reaches for the word 'soft failure.'
Sections
When a recipient is doing badly, the implant can tell you a great deal about itself. Impedance telemetry, integrity testing, ECAP, and electrical-field measures let you localize a fault to the array, the receiver-stimulator, or the tissue interface, and crucially let you separate a device problem from a biological or programming one.
Sections
When telemetry or symptoms say something is wrong inside the cochlea, imaging shows you where. From a quick transorbital plain film to flat-panel cone-beam CT, the implanted ear can be imaged to confirm position, catch tip fold-over before the wound is closed, and distinguish a scalar translocation from a migrated array.
Sections
Most implants run for decades, but a minority must come out. When they do, the reassuring lesson of three decades of data is that going back through the old path usually restores the hearing the patient had before — and sometimes a little more.
Sections
An implant is a magnet and a sensitive electronic package living under the scalp for life. Most of the modern world is safe around it — but a handful of energies, from the MRI bore to a static-charged playground slide, deserve respect.
Sections
Children are not small adults around an implant: they get more ear infections, their skulls are still growing, they handle the device roughly, and they cannot always say what is wrong. A good programme answers each of these with a deliberate system of prevention.
Sections
A million people hear with implants, yet the same handful of unsolved problems drives every device on this chapter's horizon.
Sections
A motor that advances the array fractions of a millimetre per second does what no surgeon's hand can: insert at a perfectly constant, gentle speed.
Sections
Instead of hollowing out the mastoid, drill one planned tunnel to the cochlea, threading past the facial nerve by a fraction of a millimetre.
Sections
An implant electrode is, biologically, a foreign body pushed into a fluid-filled tube of delicate neural tissue. The cochlea answers with inflammation, fibrosis and slow cell death that raise impedance and erode residual hearing. The pharmacological electrode turns the array from an inert wire into a tiny drug-delivery device — most concretely a steroid reservoir, and in the longer view a source of neurotrophins that could keep the auditory nerve alive and even draw it closer.
Sections
Today's arrays carry on the order of twenty hand-assembled platinum contacts on a moulded silicone carrier. Micro-fabrication promises something different: thin-film and MEMS arrays with dozens of tiny contacts, polymer carriers thin and flexible enough to hug the modiolus without tearing the cochlea, and even sensors built into the array. But more contacts is not the same as more independent channels — the lesson next-generation arrays must respect.
Sections
Every limitation of the cochlear implant converges on one place: the gap between the metal contact and the neurons it is trying to address. Current must cross conductive perilymph to reach the spiral ganglion, and on the way it spreads, so channels overlap. The real bottleneck is not how many contacts you build but how cleanly each one can speak to its own population of neurons. Three strategies attack the gap — focus the current, move the contacts into the nerve, or pull the nerve back to the contacts.
Sections
Every cochlear implant today still leaves something on the head: a coil, a magnet, a processor behind the ear. The totally implantable cochlear implant aims to put all of it under the skin so that hearing is simply always there. The vision is compelling and the prototypes exist, but three hard problems keep it investigational.
Sections
If the processor and battery were the only obstacles, the totally implantable implant would already be here. The real crux is the microphone: a sensor sealed under the skin hears the body as loudly as the world. Pair that with the problem of powering electronics that never come off, and you have the two engineering bottlenecks of invisible hearing.
Sections
While engineers wrestle with putting the implant under the skin, the processor on the outside is getting much cleverer. Deep learning now cleans speech from noise, classifiers pick listening settings automatically, and data logging quietly informs care. The gains are real but bounded - a smarter signal still has to squeeze through a blurry electrode-neuron interface.
Sections
A cochlear implant is a device that needs lifelong tending, yet the expert who tends it may sit hundreds of kilometres away. Teleaudiology moves the map, the check-up, and increasingly some of the adjustment itself across a network connection - and, for selected tasks, the outcomes hold up.
Sections
The mammalian cochlea cannot replace a lost hair cell or a dying spiral ganglion neuron. Regenerative biology asks whether we can change that - either to one day spare a patient the implant, or, more realistically near-term, to rebuild the neural substrate the implant must stimulate.
Sections
For one specific genetic deafness, the most striking recent result in the whole field is not a better electrode - it is children who could not hear, hearing after a single injection into the cochlea. OTOF gene therapy is the first credible biological alternative to an implant, for a narrow but real group.
Sections
Electrical current spreads. Light can be focused. That single physical fact is the reason a group in Gottingen has spent fifteen years trying to replace the electrode with an array of micro-LEDs and to teach the auditory nerve to listen with light. The science is real and the rodent results are striking, but every part of it is still preclinical, and the path to a human ear runs through gene therapy.
Sections
Programming a cochlear implant is slow, expert-dependent, and largely behavioural: it leans on what the patient can tell the audiologist over repeated visits. A long-running ambition is an implant that measures itself and tunes itself. Parts of that vision are quietly already in the clinic; the fully self-tuning device is not.
Sections
The preceding chapters each pull on one thread: gentler surgery, drugs at the electrode, neurotrophins to coax neurites toward the array, light instead of current, AI in the processor, biology to repair the cochlea. The bionic ear is what happens when those threads are woven together. The honest version of that story is staged, uneven, and humbling, and it is meaningless if most of the world still cannot get a basic implant.
Sections
The implant was built for speech and delivers it. Music is the signal it struggles with most, and that contrast is the whole story.
Sections
Pitch, timbre and rhythm are the acoustic dimensions of music, and how the normal ear hears them is the yardstick for judging electric hearing.
Sections
Envelope coding preserves the rhythm of music and discards almost everything else: this trade-off is the engine of the whole chapter.
Sections
Of all of music's dimensions, pitch is the one the implant degrades most. Place-pitch is coarse and distorted, temporal-pitch saturates within a few hundred hertz, and the casualty is melody: strip away rhythm and many recipients recognise familiar tunes barely above chance.
Sections
Timbre is what lets us tell a violin from a trumpet on the same note. It lives in the fine shape of the harmonic spectrum and in the attack of each tone - and the implant blurs the first while partly sparing the second, leaving recipients struggling to name instruments and often complaining that everything sounds harsh, dull or alike.
Sections
Where pitch and timbre fail, rhythm comes through. Beat, tempo and rhythmic pattern ride on the temporal envelope - the one part of the signal the implant reproduces faithfully - so recipients perceive rhythm at or near normal-hearing levels. It is the channel rehabilitation should build on, and the reason a tune lost to melody can still be recognised by its beat.
Sections
A single sung line can be followed; a chord, a choir, or a band tends to collapse into a single rough texture. With only a handful of broad frequency channels, the implant cannot pull simultaneous pitches apart, so harmony blurs and the melody hides inside the mix.
Sections
How do we score something as personal as music? Clinicians separate what a listener can discriminate (perception) from how much they enjoy it (appraisal), then use structured test batteries and questionnaires to measure each, because the two do not always move together.
Sections
If music suffers because the signal is stripped of detail, would a smarter coding strategy restore it? Fine-structure strategies, current steering and higher rates all aim to add the pitch information music needs, but the gains are real-world modest, because the electrode-neuron interface ultimately caps what any code can deliver.
Sections
Even an implant that fits speech beautifully can make music sound shifted or sour. The reason is geometry: the processor's frequency table assigns incoming sound bands to electrodes whose tonotopic cochlear address may not match the pitch those bands are supposed to evoke. This module unpacks frequency-to-place mismatch, why it especially corrupts melody and harmony, the across-ear mismatch that troubles bilateral and bimodal users, and the place-based allocation strategies designed to put the notes back where the cochlea expects them.
Sections
Adults who lose hearing late often grieve the music they remember; children implanted early have no such comparison. For them, electric hearing is simply hearing, and many grow up singing, taking music classes, playing instruments and reporting genuine enjoyment. This module explores the developmental and plasticity advantage of early implantation, how music threads through language, social and emotional growth, and why - despite the same degraded pitch - early exposure and family engagement matter more than raw perceptual accuracy.
Sections
If one change could most improve how music sounds through an implant, it is adding back real acoustic hearing. Whether it comes from a hearing aid in the opposite ear (bimodal) or from low-frequency hearing preserved in the implanted ear (electric-acoustic stimulation, or hybrid), acoustic low-frequency hearing delivers the fine temporal structure and resolved low harmonics that carry pitch and melody. This module explains why bimodal and EAS listeners outperform electric-only listeners for melody, timbre and enjoyment, and what it means for hearing preservation and fitting.
Sections
Music perception through an implant is not fixed at activation. With structured, focused listening practice, recipients can sharpen timbre and melodic-contour recognition and, even more reliably, recover enjoyment. This module covers what to train, how to train it at home or by telecare, and how to set goals that the implant can actually deliver.
Sections
Music is not only a perception task to be scored. It is pleasure, memory, identity and connection. Many recipients value music deeply even when their measured perception is poor. This module examines the perception-enjoyment gap, what makes music enjoyable through an implant, and how to counsel recipients and families honestly and hopefully.
Sections
Music is the hardest test an implant faces, and it is becoming the benchmark by which the next generation will be judged. This module stages the advances most likely to let an implant carry a melody, from incremental coding and channel improvements available now to the paradigm shifts (optical stimulation, biological repair) that could finally deliver the spectral resolution music demands.
Sections
The electrode that restores hearing sits in an ear that often also carries tinnitus and broken balance. The same technology touches two further problems.
Sections
Most severely deaf ears also ring. The phantom sound is born not in the dead cochlea but in a brain straining to hear, turning up its own gain.
Sections
The implant fights tinnitus on several fronts at once: it feeds the starving brain, masks the phantom, scrambles its signal and steals its attention.
Sections
Most recipients who arrive with bothersome tinnitus leave with it quieter or gone. A smaller group is unchanged, and a small minority is worse or develops new tinnitus. The data are encouraging but messy, and the honest summary is a probability, not a promise.
Sections
Single-sided deafness is where the implant's tinnitus benefit is on firmest ground. The dead ear often carries the worst, most intractable tinnitus, and putting electrical hearing back into that ear is the one intervention that treats both the silence and the noise.
Sections
For a minority, the implant does not quiet the tinnitus — and a smaller number leave with it louder, or with a new tinnitus they never had. These are the cases that test counselling and patience, and the honest position is that we cannot yet reliably predict who they will be.
Sections
For many candidates the ringing is the real reason they walk through the door. The implant usually helps the tinnitus, but it is not a tinnitus device, and the honest conversation is the one that promises a likely benefit, names the small risk of worsening, and keeps every established tinnitus treatment on the table.
Sections
The cochlea and the balance organs share one continuous fluid-filled labyrinth, so an electrode threaded into the scala tympani is never far from the vestibular receptors. Most recipients compensate, but a measurable fraction lose vestibular function on testing and a smaller group becomes symptomatically dizzy, which makes balance part of the implant's cost ledger.
Sections
If the implant can cost balance, the team should know what each ear's labyrinth is worth before choosing where to operate. A short history and bedside screen, backed by targeted canal and otolith tests, documents the baseline, points to the safer ear, and gives a reference for the recipient who turns up dizzy afterwards.
Sections
The cochlear implant taught us that a missing inner-ear sense can be rebuilt with electricity. The vestibular implant asks the same question of balance: can we replace the signal a destroyed labyrinth no longer sends?
Sections
A vestibular implant must do what the labyrinth does: sense head rotation, convert it into a neural code, and deliver that code to the right nerve branch. Each step is an engineering compromise.
Sections
The labyrinth signals rotation as a push-pull between two ears. A single implant has to recreate that conversation from one side, then trust the brain to learn the new accent.
Sections
After two decades of bench work, vestibular implants have entered human ears. The honest answer to "does it work?" is a guarded yes: recipients regain part of the vestibulo-ocular reflex, see more steadily when they move, stand and walk with less wobble, and report a life less dominated by dizziness. But the restored signal is incomplete, the eyes must learn to trust an artificial one, and the device remains an investigational tool, not a routine therapy.
Sections
The vestibular implant has a hidden cost. The electrodes that reach the balance nerves sit dangerously close to the cochlea, and in most early recipients the implanted ear lost hearing. That trade-off has shaped the field's most pragmatic idea: if the ear is going to give up its hearing anyway, why not restore both senses at once? The combined cochleovestibular implant aims to rebuild hearing and balance in a single operation.
Sections
The cochlear implant restored hearing. Then it was asked to quiet tinnitus. Now its descendants reach for balance. The horizon of this chapter is a single implanted platform that serves hearing, tinnitus, and the vestibular sense together — not three operations, but one. Getting there demands better electrodes, smarter motion sensing, closed-loop fitting, and trials that move the vestibular implant from the laboratory into the clinic, without leaving most of the world's patients behind.
Sections
The cochlear implant is one rung on a ladder of implantable hearing solutions. Knowing where it stops and another device begins is the first clinical skill of this chapter.
Sections
Air, bone, direct-drive, electric. Four routes carry sound into the cochlea, and the device classes that use them sort neatly onto a single map of anatomy and hearing loss.
Sections
Shake the skull and both cochleae hear. The physics of how vibration reaches the inner ear explains why bone conduction bypasses a diseased middle ear and why it never quite belongs to one side.
Sections
A titanium fixture osseointegrates into the skull and a small abutment pierces the skin, letting the processor drive bone directly with nothing in the way. This is the original implantable bone-conduction design and still the efficiency benchmark.
Sections
Replace the skin-piercing abutment with a pair of magnets and the skin can stay closed. The external processor and transducer cling to an implanted magnet, trading skin breakdown for the price of pushing vibration through living tissue.
Sections
Put the transducer itself under the skin and the vibration never has to cross soft tissue. Active transcutaneous implants like the Cochlear Osia and the MED-EL Bonebridge drive bone directly while leaving the skin closed, recovering the output that passive magnet systems lose.
Sections
From the percutaneous abutment to the active transcutaneous lift: how bone-conduction implants are placed, how the skin is managed, and how complications are graded and prevented.
Sections
Instead of pushing air into the ear canal, active middle-ear implants vibrate the ossicular chain or round window directly. Meet the floating mass transducer and the fully implantable systems built around it.
Sections
Incus, stapes, oval window or round window - the coupling site decides which hearing loss an active middle-ear implant can fix. Here is how couplers, placement and revision work.
Sections
For an ear that blocks sound rather than fails to sense it, a bone-conduction or middle-ear device drives the working cochlea directly. This is the central indication for implantable hearing devices that are not cochlear implants.
Sections
For single-sided deafness, CROS aids and bone-conduction devices reroute sound to the good ear, but only a cochlear implant puts hearing back into the deaf ear and restores true binaural listening.
Sections
Each implantable hearing device has an audiometric box it is built for. Mastering those indication ranges, plus trials, imaging and honest counselling, turns the audiogram into a device-selection map.
Sections
Across bone-conduction devices and active middle-ear implants the headline numbers look impressive, but the trials are small and heterogeneous. This module separates what the evidence reliably shows from what it cannot yet tell us.
Sections
Five hearing-restoration options, one patient. This module turns the audiogram, the pathology, the anatomy and the patient's own priorities into an explicit pathway from problem to device.
Sections
For a child with microtia and atresia, a softband today and an implant later can keep an ear in the game during the years that matter most. Looking further out, the boundaries between these devices and the cochlear implant are beginning to blur.
Sections
A cochlear implant assumes a working cochlear nerve. When that nerve is absent, avulsed, or destroyed by tumour, hearing can still be restored by stimulating the next station up the pathway: the cochlear nucleus.
Sections
The ABI aims for a structure barely a square centimetre across, on the floor of the lateral recess of the fourth ventricle, surrounded by nerves and vessels that explain almost every non-auditory side effect the device can cause.
Sections
The auditory brainstem implant began in 1979 as a single ball electrode on the brainstem of one NF2 patient and grew, over four decades, into a multichannel device that can give selected non-tumour patients and deaf children open-set speech.
Sections
When the cochlear nerve itself is gone, a cochlear implant has nothing to drive. The ABI bypasses the nerve and stimulates the cochlear nucleus directly, but only after the nerve has been proven unusable.
Sections
Strip away the array and an ABI is essentially cochlear-implant hardware. The defining difference is a flat paddle of surface electrodes laid on the brainstem instead of a thread wound into the cochlea.
Sections
In neurofibromatosis type 2 the tumour and its removal reshape the very landmarks the surgeon needs to place the electrode, which is a large part of why NF2 results trail every other ABI group.
Sections
In adults whose cochlea or cochlear nerve has failed but whose brainstem is intact, the auditory brainstem implant performs far better than it does after vestibular schwannoma surgery, sometimes approaching cochlear implant levels.
Sections
For children born with no cochlear nerve or an uninplantable cochlea, the brainstem implant offers the only route to sound, but only if it reaches a young, plastic auditory brain in time.
Sections
The surgeon must seat a flat electrode paddle on a cochlear nucleus that cannot be seen, reaching it through the foramen of Luschka and reading the brainstem by its landmarks alone.
Sections
The cochlear nucleus has no visible borders, so the surgeon places the ABI paddle blind and lets electrically-evoked brainstem responses and cranial-nerve monitoring decide whether the position is right before the skull is closed.
Sections
The first switch-on of an ABI happens with a crash cart nearby, and every electrode is then interrogated one by one for sound versus side-effect, making the fit slower, more personal and less predictable than any cochlear implant.
Sections
Sitting on an open patch of brainstem, ABI electrodes are millimetres from nerves and tracts that have nothing to do with hearing, and the tingles, twitches and dizziness they trigger are the single biggest limit on how many channels a recipient can actually use.
Sections
For most recipients an auditory brainstem implant restores sound awareness and powerfully boosts lip-reading; open-set speech is the exception in NF2 but far more common in non-tumour adults and children. Counselling has to match the group.
Sections
Wherever a working cochlear nerve survives, a cochlear implant outperforms an auditory brainstem implant, because the CI exploits the exquisite encoding of cochlea and nerve while the ABI must write directly onto a coarse brainstem map.
Sections
When even the cochlear nucleus surface fails to give precise pitch, the next target is the inferior colliculus. The auditory midbrain implant and penetrating arrays chase tonotopic access deeper into the brain, and their lessons are shaping the future of central auditory prostheses.
Sections
The cochlear implant is, at once, a celebrated medical achievement and, to many in the Deaf community, a threat to a thriving language and culture. This chapter holds both truths.
Sections
For many Deaf people, deafness is not a loss but a way of being in the world, anchored in a visual language, a shared history, and a community with its own arts, schools and norms.
Sections
The medical model treats deafness as a deficit to be corrected; the social or cultural model treats it as human variation and identity. Much of the cochlear-implant controversy is a collision of these frameworks.
Sections
How the cochlear implant became a flashpoint between medicine and the signing Deaf community, and how that debate matured from confrontation in 1991 toward a more nuanced position by 2000 and beyond.
Sections
The strongest case for implanting young children rests on a closing window for spoken language; the strongest objection rests on making an irreversible, identity-shaping choice for a child who cannot consent. Both deserve their best form.
Sections
What does the 'best interests of the child' standard actually require here, where do the limits of parental authority lie, and what must families truly understand before they choose? A look at genuinely informed, shared decision-making.
Sections
Joel Feinberg argued that children hold rights in trust to options they will value as adults. Both implant advocates and Deaf advocates claim this argument, and the most defensible reading keeps two doors open at once.
Sections
Beneath the culture war over cochlear implants sits a danger both camps recognize: a child who reaches school age without a fluent first language. Language deprivation reframes the debate from which language to guaranteed early language.
Sections
Rather than choosing between a cochlear implant and sign language, many families and clinicians now pursue both. The evidence is encouraging but genuinely contested, and honest practice acknowledges where it remains unsettled.
Sections
The social model and the expressivist objection challenge the very idea that the implant solves a problem located in the deaf body. This module lays out the critique, the medical reply, and why the choosing adult and the implanted infant are not the same ethical case.
Sections
A cochlear implant is one of medicine's success stories and one of its most unevenly distributed. This module maps the disparities by income, race and country, the enormous global gap, and how justice arguments sit alongside support for sign language and Deaf education.
Sections
Prenatal and preimplantation testing can now select against, or controversially for, a deaf child. This module lays out the science, the cases that made headlines, and the collision between reproductive autonomy, disability rights and the welfare of the future child, presented even-handedly.
Sections
How to support hearing parents of a newly identified deaf child without steering them: presenting the implant pathway and sign language as equally legitimate, and connecting families to Deaf adults and unbiased early intervention. Educational, not clinical advice.
Sections
When a competent adult decides for themselves, autonomy is paramount and the ethics shift. This module contrasts the identity journeys of the congenitally, culturally Deaf adult and the late-deafened adult, and the duty to respect either choice. Educational, not clinical advice.
Sections
How the polarised implant-versus-Deaf-culture framing has matured into implant-and-language-access, where consensus is emerging, what still divides, and a respectful synthesis for the clinician. Educational, not clinical advice.
Sections
A polished quiet-booth score is not a promise of an easy dinner party. This chapter maps the distance between clinic performance and the noisy, reverberant, multi-talker world the recipient actually lives in.
Sections
For a cochlear implant user, noise is not a nuisance but the central daily obstacle. Understanding signal-to-noise ratio, masking and the cocktail party explains why a CI needs a far cleaner signal than a normal ear to reach the same words.
Sections
Even in silence, a room can defeat an implant. Reverberation smears the very envelope the device depends on, and every step away from a talker quietly erodes the signal-to-noise ratio.
Sections
Before any clever coding happens, sound must be captured. Where the processor's microphone sits, and how many there are, quietly shapes everything the recipient eventually hears.
Sections
Two microphones can be combined to listen harder toward the front and reject sound from behind. Done well it rescues conversation in noise; done blindly it can throw away the very voice you wanted.
Sections
When noise and speech arrive from the same place, directionality cannot help. Single-channel noise reduction tries to scrub the signal instead, and it usually buys comfort more than raw clarity.
Sections
Modern sound processors listen to the listener's world, classify the scene, and silently retune directionality, noise reduction and gain so the user does not have to. We explain how automation works, what the evidence shows, and when a manual program still earns its place.
Sections
The single most powerful way to win the battle against noise and distance is to put the microphone next to the talker's mouth. We explain how remote, FM and digital-modulation systems route a clean voice straight to the processor, the very large real-world SNR gains, and how to connect them.
Sections
A small coil of wire turns a magnetic field into sound, letting a processor tap directly into the audio of a theatre, a place of worship, a service counter or a transit announcement. We explain how telecoils and induction loops work, where they shine, the decline-and-revival debate, and how they compare with newer wireless options.
Sections
When sound travels electrically from a phone or television straight into the processor, the room disappears. This module follows the signal from proprietary 2.4 GHz links to made-for-iPhone, ASHA and the broadcast world of LE Audio and Auracast.
Sections
A modern cochlear implant sits at the centre of a small constellation of streamers, microphones, remotes and apps. This module maps that ecosystem and shows how it serves bilateral and bimodal users with both ears at once.
Sections
Even a perfectly programmed implant cannot make a doorbell visible or a lecture captioned. This module looks at the wider layer of alerting systems, captioning and legal accommodations that, together with the device, deliver real-world access.
Sections
A perfect score in a quiet booth says little about a noisy restaurant. This module shows how speech-in-noise tests, datalogging, and self-report questionnaires together capture how an implant actually performs in daily life.
Sections
Technology only goes so far; the rest is strategy. This module covers realistic expectations, communication-repair and self-advocacy skills, shaping the environment, matching the right tool to each situation, and the link to auditory training.
Sections
The next leap in real-world hearing will come less from electrodes than from intelligence and connectivity: deep-learning denoising, smarter scene analysis, ubiquitous broadcast audio, and brain-steered listening.
Sections
Objective measures are the electrophysiological responses the cochlear implant itself lets us record — no behavioural report required. This module sets out what they are, why they matter across the CI pathway from theatre to the mapping booth, and the F/T/C reader-level scheme used throughout.
Sections
The first number every CI session produces. Impedance telemetry reports the health of each electrode-tissue interface — open and short circuits, the effect of fibrosis and new bone, and what the transimpedance matrix adds about electrode position.
Sections
The electrically-evoked compound action potential — the synchronous firing of the auditory nerve recorded through the implant's own electrodes. How the recording works, and why artifact rejection (forward masking, alternating polarity) is the whole game.
Sections
From a single ECAP to the measures that matter: the ECAP threshold (tNRT/tECAP), the amplitude growth function and its slope, the recovery/refractory function, and spread of excitation along the array.
Sections
The electrical stapedius reflex — an objective upper-bound on comfortable loudness. How it is recorded intra- and post-operatively, its relationship to C/M levels, and its strengths and limits as a fitting anchor.
Sections
The electrically-evoked auditory brainstem response — wave eV and friends. When the auditory nerve and brainstem integrity question outruns what ECAP can answer: ANSD, cochlear nerve deficiency, and ABI candidacy.
Sections
Electrically-evoked cortical auditory responses — the P1-N1-P2 complex and the P1 latency as a biomarker of central auditory maturation in implanted children.
Sections
Recording the cochlea's own acoustically-evoked response through the implant during insertion, to detect trauma and preserve residual hearing. The bridge between this atlas and the ECochG Atlas.
Sections
How objective measures translate into a usable MAP — predicting T and C levels, profile-based fitting, and the special value of objective data when behavioural responses are unreliable, as in young children.
Sections
Where the measures earn their keep: ANSD, malformations, device soft- and hard-failure workup, facial-nerve stimulation, and non-auditory percepts — read through worked cases.
Sections
The same physiology under three different names. A terminology map and feature comparison across Cochlear (AutoNRT / NRT), MED-EL (ART), and Advanced Bionics (NRI), with the defaults and quirks that matter at the chair.
Sections
Interactive infrastructure: amplitude-growth and spread-of-excitation plotters, a tNRT→C-level estimator, an artifact-rejection simulator, plus links to the glossary, references, and progress dashboard.
Sections
Where objective measures are heading: AI and machine learning for automated detection and data-driven fitting, panoramic ECAP and cochlear-health mapping, eASSR objective thresholds, continuous electrocochleography, closed-loop and remote programming, totally implantable devices, optogenetic stimulation, and the data, standardisation, and equity questions that decide who benefits.
Sections